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ABSTRACT 
 
Remarkable progress has been made in the development of effective 
treatments for patients with rheumatoid arthritis (RA). To ensure that a patient is 
optimally responding to treatment, consistent monitoring of disease activity is 
recommended. Established composite and individual disease activity measures 
often cannot be computed due to missing laboratory values. Simplified measures 
that can be calculated without a lab value have been developed and previous 
studies have validated these new measures, yet differences in their performance 
compared with established measures remain. Therefore, the goal of my doctoral 
research was to examine and evaluate disease activity and composite measures 
to facilitate monitoring of response in clinical care settings and inclusion of 
patients with missing laboratory values in epidemiological research.   
 In the first study, the validity of two composite measures, the Clinical 
Disease Activity Index (CDAI) and the Disease Activity Score with 28 joint count 
(DAS28) was examined and both were significantly associated with a 
rheumatologist’s decision to change therapy (CDAI OR=1.58; 95% CI: 1.42, 1.76) 
(DAS28 OR=1.34; 95% CI 1.27,1.56). However, further evaluation using receiver 
operating characteristic (ROC) analysis found that they were not strong 
predictors of physician decisions to change therapy (AUC=0.75, 0.76, 
respectively). Thus, they should not be used to guide treatment decisions in the 
clinic.   
  
 
vii
Two measures of disease activity, erythrocyte sedimentation rate (ESR) 
and C-reactive protein (CRP) are often not measured and impede the 
computation of composite measures of disease activity. In the second study, 
significant factors which may predict the measurement of the ESR and CRP were 
identified and included physician and clinical variables but no quantitative 
disease activity measures. Thus the suitability of the ESR and CRP as measures 
of disease activity is suspect.   
 In the final study, I created a new composite measure, the modified 
disease activity score with 28 joint count (mDAS28), by replacing the laboratory 
value in the DAS28.  The mDAS28 was then validated by comparing its 
performance with the DAS28. The measures were strongly correlated (r=0.87), 
and strong agreement was found between the two measures when categorizing 
patients to levels of disease activity (ĸ=0.77) and treatment response (ĸ=0.73). 
Therefore, the mDAS28 could be used in place of the DAS28 when laboratory 
values needed to compute the DAS28 are missing.  
In summary, I found that the CDAI and DAS28 were not strong predictors 
of the rheumatologist’s decision to change therapy. I also found that the 
variability in the measurement of ESR and CRP was not associated with disease 
activity. I was able to modify the DAS28 by replacing the laboratory measure and 
create a new simplified measure, the mDAS28. I also validated the mDAS28 for 
use in the clinic and in epidemiological research when the DAS28 is unavailable.   
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1.1 Description and Consequences of Rheumatoid Arthritis  
Rheumatoid arthritis (RA) is a systemic, chronic condition that can cause 
joint damage and destruction, disability and death (1). RA occurs worldwide and 
affects about 1% of the adult population (2). In the United States, approximately 
2.1 million people are affected (1). The disease is about 5 times more prevalent 
in indigenous peoples of North America compared with Caucasians in Europe 
and North America. Asian and African populations have a much lower prevalence 
of RA (1).   
The disease is characterized by joint pain, stiffness and swelling due to 
synovial inflammation and effusion. It has a variable disease course among 
patients with frequent flares and fluctuations in disease activity. The disease is a 
heterogeneous disorder with multifaceted clinical features between patients (1). 
Common symptoms of RA include tenderness and swollen joints, pain, stiffness, 
limited range of motion in joints, loss of appetite, muscle pain and skin nodules 
(3).  RA can begin in any joint and commonly begins in the smaller joints of the 
fingers, hands and wrists. Management of the disease is made difficult due to 
this multi-faceted nature.  Frequent assessment of disease activity is necessary 
to ensure effectiveness of treatment, but assessment using only a single 
quantitative disease measure such as an acute phase reactant or joint count is 
inaccurate for groups of patients (4).   
The cause of RA is unknown. RA occurs 2 to 3 times more often in women 
then in men, which suggests possible hormonal factors triggering or modulating 
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the onset of the disease.  In addition, gender appears to influence the phenotype 
of the disease with more women experiencing structural joint damage and more 
men affected by erosions to the bones. The peak age of onset of adult RA is 
between 40 and 60 years old but can begin as early as the second decade. 
Recent research suggests that the age of onset is shifting towards later in life but 
this trend could be artifactual and due more to the increase in an aging 
population. Patients with RA may become considerably catabolic and also may 
experience significant anorexia and malnourishment. On the other hand, 
sedentary and extremely poor eating habits in other patients with RA may lead to 
obesity impacting already damaged weight bearing joints and other organ 
systems. Other factors which influence the course and outcome of the disease 
are formal education and marital status as well as smoking (1).   
The consequences of RA are substantial (5). Affected individuals 
experience significant joint damage and destruction and RA is associated with 
several comorbidities, notably cardiovascular disease, which increases the 
mortality rate of affected individuals.  As the disease progresses, a patients’ daily 
activities and functional status are affected.   RA has a substantial economic 
impact with over $26-$32 billion spent annually on long-term care and loss of 
employment (2). The enormous individual patient and economic consequences 
of RA can only be prevented by treatment with effective therapeutic agents and 
consistent disease activity monitoring to ensure that treatment is effective (6, 7). 
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1.2 Contemporary Treatment of Rheumatoid Arthritis 
 
The therapeutic aim in rheumatoid arthritis is to achieve maximum 
response to treatment and the lowest disease activity level, ideally remission (8, 
9). Up until the last decade, treatment options for RA were sparse and the few 
treatments that were available were prone to toxic side-effects and often not 
effective (1). Surgery was the mainstay of treatment especially to correct 
deformities and most patients became disabled (1). Over the last decade, the 
development of new and effective treatments especially disease modifying 
antirheumatic drugs has substantially improved the prognosis for patients with 
RA with many patients now experiencing lower disease activity and remission (9).   
There are several different classes of drugs used to treat RA. Two kinds 
target pain relief and reduce inflammation but do not prevent tissue injury or 
progressive joint damage (10). They include: nonsteroidal anti-inflammatory 
drugs (NSAIDs) and analgesic drugs. NSAIDs include aspirin, ibuprofen, 
indomethacin, and COX-2 inhibitors such as valdecoxib and celecoxib and low 
dose corticosteroids or prednisone. Analgesic drugs include: acetaminophen, 
propoxyphene, meperidine, morphine and tramadol.  
A more effective class of drugs includes the disease modifying 
antirheumatic drugs (DMARDs) (10).  These drugs and to some extent 
glucocorticoids can control active synovitis and impede joint damage and 
destruction, but cannot reverse existing joint deformities or erosions. DMARDs 
are normally used in combination with NSAIDs and/or prednisone. Examples of 
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these drugs include:  Methotrexate (MTX), injectable gold, penicillamine, 
azathioprine, chloroquine, hydroxychloroquine, sulfasalazine and oral gold.  
MTX, a component of most treatment regimens, has the highest retention rate 
compared with other DMARDs (6). 
Recently, several new DMARDs, biologic response modifiers (biologics), 
were introduced, expanding the therapeutic armamentarium against RA (11). In 
addition to reducing inflammation, they can prevent joint damage but act 
differently than traditional DMARDs. These new DMARDs modify the immune 
system by inhibiting the production of proteins called cytokines, which contribute 
to inflammation. Examples of these drugs include: etanercept, infliximab, 
adaliumumab and anakinra.  Clinical trials of these agents have reported that 
they may be more effective than traditional DMARDs because, in addition to 
halting symptoms of the disease, they also slow disease progression. Although 
highly effective, these agents are expensive with an annual treatment cost of 
$12,000 to $16,000. Clinical trials have also reported variability in the response 
of patients to these agents. Not all patients respond well to these agents, with 
many developing adverse effects, attesting to the heterogeneity of the disease 
(11).   
Treatment recommendations from the American College of Rheumatology 
(ACR) published in 2008 (9) recommend aggressive treatment immediately after 
the patient is diagnosed to achieve tight control of disease activity and prevent 
bone and joint destruction. Several studies (12-14) have reported that aggressive 
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treatment of RA can prevent joint damage and thus prevent loss of function, loss 
of ability to work and expensive medical costs and surgery. Evidence that 
treatment of RA is more effective in the early stages includes several 
observational studies (12, 13, 15-17), which report substantial erosions of the 
bone occur in the first 2 years of the disease.  
The ACR also recommends on-going measurement of disease activity to 
guide in the treatment decisions made by physicians and to ensure treatment 
effectiveness (9). A number of composite disease activity measures are available 
to rheumatologists but some have limitations when used in a clinical setting (18). 
They often cannot be calculated due to missing laboratory values, and thus, 
disease activity and treatment response cannot be measured in clinical care. In 
epidemiological research using observational registry data, patients with missing 
laboratory values, and thus missing composite disease activity scores, are often 
excluded from analyses, reducing the available cohort and most likely biasing the 
study results. For new DMARD therapies to demonstrate effectiveness in 
decreasing and preventing further joint damage, feasible measures to facilitate 
the consistent and accurate measurement of disease activity and response to 
treatment must be available for use in clinical care and in epidemiological 
research using registry data.   
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1.3 Measurement of Disease Activity and Treatment Response 
1.3.1 Clinical Trials: Standard Composite Measures  
Measurement of disease activity and response to treatment is complex 
due to the multifaceted nature of RA. No single quantitative ‘gold standard’ 
measure can assess and monitor disease activity (19, 20). Clinical trials have 
been the main source of information about the efficacy of new treatments for RA. 
In clinical trials, a variety of measures have been used (20).  Up until the early 
1990s, up to 10 different individual measures of disease activity representing 
different aspects of the disease, ranging from grip strength to joint counts to two 
acute phase reactants (APR) (21), the erythrocyte sedimentation rate (ESR) (22) 
and C-reactive protein (CRP) (23), were used to assess disease activity (24-27). 
Analyses of clinical trial results were hampered by these multiple individual 
measures for several reasons: the inability to directly compare the efficacy of 
new drugs to a common standard, potential reporting of only outcome measures 
that demonstrated an impressive result and the risk of a Type I error from 
multiple statistical testing (24). To standardize measurement of disease activity in 
clinical trials, it was recommended by the international rheumatology community 
that clinical trials measure a uniform core set of seven disease activity endpoints, 
each representing one component of the disease (28). Table 1.1 lists these 
endpoints: 
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       Table 1.1 Core set of seven disease activity measures for clinical trials  
Domain  Disease Activity Measures  
Physician-reported 
         
         Disease activity 
 
Tender joint count (20, 24) 
          
         Disease activity 
 
Swollen joint count (24) 
          
         Disease activity 
 
Physician Global Assessment (20, 24)  
Patient-reported 
         
         Pain 
 
Pain Assessment (20, 24) 
         
         Disease activity 
 
Patient Global Assessment (20, 24) 
         
         Physical function 
 
Often measured by the HAQ (20, 24)  
Lab Values –measurement of one lab value  
         
        Disease Activity 
 
ESR(24) or CRP(24)  
 
HAQ- Health Assessment Questionnaire; ESR-Erythrocyte Sedimentation 
Rate; CRP- C-reactive protein.  
 
 
Use of this core set of seven individual measures in clinical trials improved 
the ability to compare results across trials. However, results were difficult to 
interpret because of multiplicity in the use of the individual measures resulting in 
a conflicting picture of efficacy (29).   To improve interpretation of results, the 
core set of endpoints were combined to form a composite index which would 
produce one score of disease activity (30). The advantages of a composite index 
over individual measures include little duplicity between measures and increased 
ability to detect changes in disease activity over time or sensitivity to change (24, 
31, 32). A study (33) reported that no single measure of disease activity could 
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distinguish between active or placebo treatment but a pooled index of these 
individual measures was effective. Therefore, the pooled index was a much more 
effective approach to assess clinic outcomes compared to individual measures. 
In addition to using composite indices in clinical trials to measure disease activity, 
criteria to measure change in disease activity or response to treatment were 
developed (34, 35).  
Composite indices are continuous measures that can quantify a patients’ 
level of disease activity into one score for ease of interpretation and 
comparability of clinical trial results. They are composed of the core set of 
individual disease activity measures (see Table 1.1) representing several aspects 
of the disease. The composite indices most widely used in randomized controlled 
trials (RCTs) are the Disease Activity Score (DAS) (19, 25, 36-38)  and its 
modified version using 28 joint count, the DAS28  (19, 25, 39-41). The DAS and 
DAS28 are continuous measures with scores ranging from 0-10. Higher scores 
indicate worse disease activity. They combine data on swollen joint count (SJC), 
tender joint count, (TJC) ESR, and the patient’s global health (PGA) measured 
by a visual analog scale.  This thesis will utilize only the DAS28 and not the DAS 
since the DAS28 is used more often in assessing disease activity. The DAS28 is 
calculated using the following formula:  
 
DAS28= 0.56 * √(28TJC) + 0.28 * √(28SJC) + 0.70 * log [ESR] + 0.014 * PGA 
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It is a simplified version of the DAS and utilizes the 28-joint tender and 
swollen joint counts instead of the more involved joint counts of the original DAS. 
The DAS28 has been shown to be as valid as the DAS (39).  
A variation of the DAS28 has been developed, the DAS28-CRP and can 
be calculated using the laboratory value CRP instead of ESR (42). It has 
received little validity testing and thus is not used very often in clinics or in 
research. In this thesis, the DAS28 containing ESR will be used.  Although there 
is no one “gold standard” measure in RA, many consider the DAS28 to be the 
gold standard and numerous studies have used the DAS28 as a comparator 
when validating new disease activity measures (16, 43-47).  
Response criteria were established for use in RCTs to determine the 
effectiveness of new treatment modalities. Response can be defined as a 
“significant or relevant change in disease activity” (19). The two most widely used 
sets of response criteria in clinical trials are the American College of 
Rheumatology (ACR) improvement criteria (19, 25, 34) and the European 
League Against Rheumatism (EULAR) response criteria (25, 35).   
The ACR improvement criteria were developed as a single score to 
measure the improvement or change from the start of treatment (baseline) to a 
given endpoint. The ACR criteria do not measure the actual state of disease 
activity. The ACR improvement criteria are comprised of the seven core set 
variables (see Table 1.1) while the EULAR response criteria, which are based on 
the DAS28 include only four (19). Usually clinical trials in RA had reported on the 
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average improvement (mean or median) of treated patients with the average 
improvement of one treatment compared to another. The efficacy of a treatment 
is determined by comparing group means of changes in disease activity 
variables. However, a significant difference between groups does not indicate the 
actual number of individual patients who responded to treatment. It was 
determined with the ACR improvement criteria that a uniform definition of 
improvement, the percentage of patients improving, could be compared across 
clinical trials. Furthermore, improvement in individual patients could be assessed. 
The definition of improvement determined by the ACR clinical trial patients is 
depicted in Table 1.2:  
 
 
                      Table 1.2 ACR improvement criteria 
 ♦ Improvement in Tender and Swollen joint 
counts 
                       
                      And improvement in 3 of the following 5 core set measures    
  
 
♦ Pain scale 
 
♦ Patient Assessment  
 
♦ Physician Assessment 
 
♦ Functional questionnaire 
 
♦ Lab value (ESR or CRP) 
 
     
          ACR-American College of Rheumatology; ESR-Erythrocyte    
         Sedimentation Rate; CRP-C-reactive protein;  
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The ACR response (ACR20) is defined as 20% improvement in tender 
and swollen joint counts and 20% improvement in 3 of the 5 core set measures in 
Table 2. ACR50, ACR70 or ACR90 reflect, 50%, 70% or 90% improvement in the 
above parameters.   
The definition of response as measured by the EULAR response criteria 
differs conceptually from the ACR improvement. Rather than defining 
improvement or no improvement, the EULAR definition classifies patients into 
three groups, no response, moderate and good response. The EULAR response 
criteria reflect two components: the present level of the disease activity score 
using DAS28 and the change in disease activity from baseline (when the drug 
was initiated) to a given endpoint. A change in disease activity of 1.2 in an 
individual patient signifies a statistically significant change (37). The EULAR 
measures the relevant change in disease activity since the start of treatment and 
the level of disease activity at the follow-up visit. Table 1.3 depicts the 
measurement algorithm for the EULAR criteria. 
 
 
Table 1.3 EULAR response criteria using DAS28  
DAS28 at endpoint  Improvement in DAS28 from baseline  
     >1.2                    >0.6 and ≤1.2              ≤0.6
 
   ≤3.2 
 
Good  
Moderate   
None 
 
   >3.2 and ≤5.1 
 
 
 
   >5.1 
 
EULAR-European League Against Rheumatism; DAS28-Disease Activity Score 
with 28 joint count 
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Minimum response to determine active treatment from placebo in clinical 
trials is assessed by ACR20 and moderate EULAR values.  Great improvement 
in the patient is indicated by ACR50, 70 and 90 and EULAR major response (48). 
 
1.3.2 Clinical Care and Epidemiological Research: Simplified Composite 
Measures 
 
The DAS28 and the response criteria measures have proven effective in 
clinical trials to measure disease activity level and response to treatment in 
groups of patients (19), but have not proven as useful in the daily practice setting 
(44) or in epidemiological research utilizing observational registry data (45). 
Since patients selected for clinical trials have a certain level of disease activity 
and since clinical trials follow patients for only a short period of time, it is not 
feasible to use the same measures of response in a clinical practice (19, 20). 
Computation of the DAS28 requires an acute phase reactant (APR), either the 
ESR or the CRP, that is oftentimes not available during the office visit preventing 
the score from being calculated at the clinical encounter (25, 49).  Few studies 
have examined the frequency of measurement of ESR or CRP in clinical care or 
the correlates associated with measurement of ESR or CRP. Large variation in 
the clinical measurement of ESR and CRP has been reported (50, 51). Physician 
practice style and training have been found to be related to measurement of ESR 
and CRP (50, 51).  In addition, uncertainty about the value of the tests may 
influence physician laboratory monitoring practices (52). Studies need to be done  
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to determine why there is variability in the measurement of ESR and CRP and 
identify correlates influencing their measurement. Illumination of these factors 
could help improve the clinical management of RA by facilitating the consistent 
monitoring of disease activity to guide treatment as recommended by the ACR 
and also improve epidemiological research studies.  
The EULAR response criteria is limited in use in the clinical care setting 
since it is derived using the DAS28. The ACR improvement criteria measure the 
percent improvement for an individual patient’s response to treatment which was 
an important measure in clinical trials.  But in clinical practice, it is more important 
to measure the actual amount of disease activity since the goal is to suppress 
disease activity then to determine the percentage of the patient’s response (19). 
Thus the ACR response criteria will be of limited use in a clinical setting since it 
does not measure disease activity levels (19).  
Two simplified composite disease activity indices have recently been 
developed to address the limitations of the DAS28 and the EULAR and ACR 
response criteria. These new measures, the Clinical Disease Activity Index 
(CDAI) (25, 53) and the Simplified Disease Activity Index (SDAI) (54) have been 
specifically designed to provide the physician with a feasible and accurate tool to 
monitor disease activity in a clinical setting.  Both are numerical scores but the 
SDAI requires the lab value CRP to be computed and thus its use may be limited 
in clinical care.  The CDAI does not require a lab value allowing it to be computed 
during the office visit to facilitate clinical decision-making while the patient is 
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present (49). It is comprised of tender joint count (TJC), swollen joint count 
(SJC), patient global assessment (PGA) and physician global assessment of 
disease activity (PhGA). The SDAI and the CDAI are calculated using the 
following formulas: 
            SDAI= 28 TJC + 28 SJC + PGA + PhGA + CRP 
 
                       CDAI= 28 TJC + 28 SJC + PGA + PhGA 
 
 
A score that can be computed without a lab value such as the CDAI was 
determined to be practical and was tested for validity in several studies (53) but 
questions still remain (18). 
Because of the variable course of RA disease, clinical management of RA 
requires repeated assessment of disease activity and the effectiveness of 
treatment (9).  One study (55), a multi-center, RCT, recently reported that 
systematic monitoring of disease activity in daily practice resulted in more 
patients with low disease activity due to more changes in DMARD treatment (6, 
56). Measures that are feasible and valid in a clinical care setting comprised of 
patients with many different presentations of the disease have not been fully 
tested or developed (19). It is clear that research efforts are needed to evaluate 
the new simplified measures for validity and feasibility in a clinical care setting. 
The availability of valid tools to measure and monitor disease activity in the clinic 
and in epidemiological research could reduce disease activity in patients and 
lead to reduction in pain, joint damage and joint destruction.  Therefore, valid 
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measures could reduce the economic impact and loss of employment for patients 
with RA and improve their quality of life. 
 
 
1.4 Simplified composite disease activity measures in rheumatoid arthritis:  
should they be used in standard care? (published previously in Clinical and  
Experimental Rheumatology 2007; 33: 506-13) 
 
 
(1) Abstract 
 
Objective: To examine the validity, reliability, and predictive value of two recently 
developed composite disease activity measures, the Simplified Disease Activity 
Index (SDAI) and the Clinical Disease Activity Index (CDAI) in rheumatoid 
arthritis (RA) patients.  
 
Methods: A systematic review of the published literature was performed 
between February 2003 and November 2007. Data was extracted regarding 
correlations of the SDAI and CDAI with standard clinical trial measures, the 
predictive ability of the measures and correlations with changes in radiographic 
scores. The ability of the measures to categorize patients according to their 
disease activity status compared to standard categories was also examined.   
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Results:  Among 17 studies initially identified, 12 provided information on the 
validity and reliability of the SDAI and CDAI. These measures were found to be 
strongly correlated with the Disease Activity Score (DAS28) with correlation 
coefficients ranging from 0.80 to 0.93. Areas under the curve (AUC), from 
receiver operating characteristic (ROC) curve analysis predicting physician 
responses, varied from 0.821 to 0.923. Moderate association with changes in the 
HAQ and radiographic scores were found with correlation coefficients ranging 
from 0.18 to 0.63. Several studies reported mixed results between the measures 
when categorizing patients according to disease severity with the SDAI and CDAI 
the more stringent at remission.     
 
Conclusions: The SDAI and the CDAI were found to have concurrent validity 
and were highly predictive of a change in therapy, but not predictive of future 
functional capacity or joint damage. Differences were found when categorizing 
patients according to disease activity level. Further studies should be conducted 
especially at remission and low disease activity status before these measures 
are used independently in a clinical setting.   
 
Keywords: rheumatoid arthritis, disease activity indices, disease activity scores 
(DAS), composite indices 
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(2) Introduction 
 
Over the last 15 years, the introduction of new and effective treatment 
agents has revolutionized the care of rheumatoid arthritis (RA) patients. Now, 
progression of joint damage and subsequent disability can be retarded due to 
aggressive pharmacological treatment with new antirheumatic drugs (57, 58). As 
a result of these advances in therapy, many patients may realize minimal disease 
activity (MDA) and even remission of the disease.  However, to optimize 
treatment with these agents and facilitate therapeutic decision-making, accurate 
and consistent monitoring of disease activity is necessary in daily clinical practice 
(55).  
In the early 1990s, the American College of Rheumatology (ACR), the 
European League Against Rheumatism (EULAR), and the World Health 
Organization/International League Against Rheumatism (WHO/ILAR) 
recommended a core set of individual measures to standardize quantitative 
measurement in clinical trials (28, 59, 60). These individual measures include: 
tender joint count (TJC), swollen joint count (SJC), patient assessment of pain, 
patient global assessment of disease activity (PGA), physician global 
assessment of disease activity (PhGA), measure of an acute-phase reactant 
(e.g., erythrocyte sedimentation rate [ESR] or C-Reactive protein [CRP]), and an 
assessment of physical function. Because the presentation of RA is highly 
variable between individual patients, a single measure cannot successfully 
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determine disease activity in all patients. Thus, these individual measures of 
disease activity were pooled into composite indices (30). The composite disease 
activity indices most widely used are the Disease Activity Score (DAS) (38, 61) 
and its modified version using a 28 joint count (DAS28) (39). In addition to 
assessing disease activity, determining improvement in patients in clinical trials 
was necessary to determine the efficacy of various treatments. The two most 
widely used sets of improvement criteria in clinical trials are the ACR 
improvement criteria (28), and the EULAR response criteria (35).     
These composite indices and improvement criteria have been validated 
and used extensively in clinical trials, but because the DAS and DAS28 are 
difficult to compute, and require extensive joint counts and laboratory results that 
are not immediately available, they have not been found to be as useful in daily 
clinical practice (62). In addition, questions remain whether these standard 
clinical trial measures that have been effective in measuring the disease activity 
and response to treatment in groups of patients can now be as effective in 
measurement of individual patients (63).       
Two new simplified composite disease activity indices that have been 
recently developed specifically for use in a daily clinical setting include the 
Simplified Disease Activity Index (SDAI) (54) and, its modified version, the 
Clinical Disease Activity Index (CDAI) (53). Both have been designed to provide 
clinicians with simpler but valid ways to assess individual patient disease activity 
and therapeutic response. In addition, the CDAI does not require an assessment 
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of an acute-phase reactant and thus can be used to measure disease activity 
and response to treatment in any setting (53).  
In a 2005 review (44), Aletaha et al. reported on the validity of the SDAI 
and CDAI, but the findings were primarily from the two studies (53, 54) that 
derived the SDAI and CDAI.  The purpose of this review is to examine and 
summarize the evidence from the body of published literature to date regarding 
the validity and reliability of these two new indices as evaluative measures of 
disease activity in individual patients and to make recommendations regarding 
their use in standard care.  
 
(3) Methods 
 
Search Strategy and Information Sources  
The literature was searched using the electronic databases PubMed, 
Medline, Medline Plus, Embase, Cochrane Database of Systematic Reviews and 
Cochrane Registry of Controlled Trials. Since this review is limited to the two new 
measures, the SDAI and the CDAI, the literature search was performed on 
literature published from January, 2003 to November, 2007. Pre-determined 
terms were used to conduct the search and included, but were not limited to, 
rheumatoid arthritis, rheumatic diseases, arthritis, disease activity index, 
composite index, disease activity indices, and composite disease activity indices. 
A second search was performed adding the names of these measures and 
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criteria sets to the first search: DAS, DAS28, ACR Improvement criteria and the 
EULAR Response criteria.  A third search was conducted adding the names of 
the two new measures, the SDAI and the CDAI. (Table 1.4) 
To be included in this review, articles had to report studies where disease 
activity was assessed by one of the newer activity measures (SDAI or CDAI).  
Articles were excluded if they were reviews, meeting abstracts or not in English.   
 
Description of the SDAI and the CDAI  
The SDAI was developed in 2003 as a simpler alternative to the DAS28. 
The SDAI is the numerical sum of five of the core set of endpoints: swollen and 
tender joint count (based on a 28-joint assessment), the PGA, the PhGA, and the 
level of C-reactive protein (CRP). 
 
SDAI= 28TJC + 28SJC+ CRP + PGA + PhGA  
  
CRP is a measure of the acute phase response and has been reported to 
be a reliable measure (49). CRP is expressed in mg/dL with a range of values 
from 0.1 to 10.0.  The SDAI results in an absolute number to measure disease 
activity as does the DAS28, but the measures differ by the weightings of the 
individual components, the lab value and the patient self-report measure. In the 
SDAI, the patient self-report measure is the PGA while in the DAS28, it is defined 
as the global health (GH). The GH differs from the PGA in that it contains several 
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different health outcomes, with some not related to RA. The SDAI is easier to 
calculate compared to the complicated formula of the DAS28:  
 
DAS28= 0.56 * √(28TJC) + 0.28 * √(28SJC) + 0.70 * ln [ESR] + 0.014 * PGA 
 
The SDAI originally was divided into the following disease activity 
categories: mild (SDAI≤ 20), moderate (SDAI >=20 and <40), and high (SDAI> 
40). Major improvement was represented by a drop in the SDAI of 22 and 
moderate improvement is a change between 10 to 22. However, new cut points 
for remission, low, moderate and high disease activity were recently redefined for 
the SDAI and are lower than those previously used (62). The newly defined cut 
points are: remission <3.3, low disease activity <=11; moderate disease activity 
<=26 and high disease activity >26, with a possible range of 0.1 to 86.     
Since the SDAI and DAS28 require the measurement of a lab value, the 
CRP or the erythrocyte sedimentation rate (ESR), immediate assessment of 
disease activity may not be possible due to a delay in the return of lab results. To 
address this problem, the CDAI was developed in 2005 as a modified version of 
the SDAI, containing the same components as the SDAI, except for the CRP. 
The CDAI is calculated from the following formula:    
 
               CDAI= 28TJC + 28SJC + PGA+ PhGA  
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The CDAI has been divided into the following disease activity categories: 
remission <=2.8; low disease activity <=10; moderate disease activity <=22; high 
disease activity >22 with a possible range of 0 to 76.   Criteria to define major 
improvement based on the CDAI have not been developed.  
 
Assessment of validity and reliability  
 The validity and reliability of the indices were assessed using the 
measurement properties proposed by the Outcomes Measures in Rheumatoid 
Arthritis Clinical Trials (OMERACT) initiative (64). The OMERACT filter (65), a 
framework for validation of outcome measures, requires that a measure have 
truth, be discriminatory and be feasible. These measurement properties are 
summarized in Table 1.5.       
 
(4) Results 
 
The search strategy described in Table 1.4 identified 1587 titles on 
composite disease activity indices in rheumatoid arthritis. After including the 
established composite indices, 342 titles remained. After specifying that the 
studies had to contain one of the new indices, the SDAI or CDAI, 17 studies 
remained. Of these, 5 were excluded because four studies were reviews and one 
study was not in English.   
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In the 12 studies in which the SDAI and/or CDAI were used, different 
measurement properties to assess the measures were investigated (several 
publications investigated more than one property):  1). Concurrent validity:  6 
publications (16, 47, 53, 54, 62, 66) (included were 2 papers from the earlier 
review and 4 new publications); 2). Predictive validity: 4 publications (15, 53, 54, 
67) (included were 2 papers from the earlier review and 2 new publications); 3). 
Construct validity: 5 publications (15, 53, 54, 62, 68) (included were 2 papers 
from the earlier review and 3 new publications); 4). Discrimination and reliability:  
9 publications (15, 16, 47, 53, 62, 66, 67, 69-71) (included was 1 paper from the 
earlier review and 8 new publications); 5). Responsiveness:  2 publications (16, 
62) (included was 1 paper from the earlier review and 1 new publication). 6). 
Face and content validity: 1 publication (62). This review will address topics 1-5 
from above. None of the 12 studies in this review formally evaluated the 
feasibility of the SDAI and CDAI in the clinical setting and this topic is not 
included in this review.     
 
 Concurrent Validity:  
Five studies (47, 53, 54, 62, 66) reported on correlations of the SDAI with 
the DAS28 (Table 1.6) and one study (16) with the DAS. Two studies (53, 54) 
previously showed that the SDAI was highly correlated with the DAS28, one 
study using data from 3 RCTs (r=0.80 to 0.93) and one using an observational 
and inception cohorts (r=0.86 to 0.90). Three studies (47, 62, 66) confirmed 
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these results.  Leeb et al. (47) reported a strong cross-sectional correlation 
(r=0.89) and strong longitudinal correlations (r=0.89, 0.85 and 0.84) over four 
time points. A second study (66), an RCT, also reported a strong correlation 
(r=0.91) between the SDAI and the DAS28. A third study (62) found the same 
result using an observational cohort (r=0.91).   
The CDAI was compared to the DAS28 in two studies (53, 66)(Table 1.6).  
One study (53) previously showed that the CDAI was highly correlated with the 
DAS28 in an observational cohort and validated the result using an inception 
cohort. One RCT (66) confirmed these results (r=0.89).  
A sixth study (16) not shown in Table 1.6, compared the SDAI with the 
DAS in an observational cohort of 200 early RA patients. Good correlations 
between the DAS and the SDAI or CDAI were found but no data was reported.  
 
Predictive Validity:  
The SDAI and the CDAI were compared with the Health Assessment 
Questionnaire Disability Index (HAQ), a measure of functional disability (29) in 
two studies (53, 54) (Table 1.6). One study (54) previously showed moderate 
correlations between the SDAI and the HAQ at baseline and 6 months in 3 RCTs 
(range r= 0.36-0.63).  The same study modified the SDAI by removing the CRP 
value and reported moderate correlations with the DAS28 in the 3 trials (range: 
r= 0.47-0.56). Aletaha et al (53) reported moderate correlations in observational 
(r=0.34, 0.48) and inception cohorts (r=0.18, 0.46) between the SDAI and the 
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HAQ at two time points. Moderate correlations between the CDAI and the HAQ 
at two time points were also found in the two cohorts (observational: r=0.34, 
0.49) (inception: r=0.18, 0.50).  
Two other studies (15, 62) reported on the SDAI and CDAI’s ability to 
discriminate between groups of patients with different functional status.   Aletaha 
et al. (53) in an observational cohort reported that the new SDAI cut points 
discriminated well between groups of patients in remission and high disease 
activity with different HAQ scores. Khanna et al. (15) in an observational cohort 
of 200 early RA patients reported similar results when using the new SDAI cut 
points and the CDAI to classify patients as either in minimal disease activity 
(MDA) or remission.  Those classified in MDA or in remission were found to have 
lower median HAQ status compared to groups who were not.  
 
Construct Validity:   
Moderate correlations were found in one study (53) that assessed 
construct validity, by comparing the SDAI and CDAI with radiographic 
progression. The study using an inception cohort of 91 RA patients, found 
statistically significant moderate correlations (SDAI: r=0.59, CDAI: r=0.54, 
p<0.0001) between the SDAI and the CDAI and the Larsen score (30).   
Several studies (15, 54, 62, 68) reported that the SDAI and CDAI 
discriminated well between groups of patients with radiographic progression. Two 
studies (54, 68) used the old SDAI cut points. Smolen et al. (54) using data from 
  
 
27
1839 patients from 3 RCTs, reported that changes in the SDAI response 
categories (major, minor or no improvement) of disease activity correlated with 
similar increases in the Sharp score. In a second study, (68)1004 patients in an 
RCT with high SDAI scores showed greater progression of joint damage when 
measured by the modified SHS. Two other studies (15, 62) used the new SDAI 
cut points. Aletaha et al. (62)using an inception cohort of 56 patients to validate 
the new SDAI cut points, reported patients classified in remission by the SDAI 
had significantly smaller changes in the Larsen score (p<0.0009) compared to 
those in high disease level. In a second study, Khanna et al. (15) reported similar 
results using a cohort of 200 patients with early RA. Patients classified according 
to new SDAI criteria and CDAI in minimal disease activity (MDA) or remission 
had a smaller change in Sharp scores compared to the patients not in MDA or 
remission.   
 
Discrimination and reliability:  
The ability of the measures to differentiate between different disease 
activity levels was assessed in nine studies (15, 62, 66, 69, 70) using the SDAI 
and in four studies using the CDAI (15, 53, 62, 69) (Table 1.7). In four studies 
(15, 53, 62, 69)  the agreement between the classifications of individual patients 
by the new SDAI cut points, CDAI and the DAS28 were compared using kappa 
statistics (72)(31) (Table 1.7). One study (62) using an observational cohort, 
reported good agreement between the activity states classified by the SDAI and 
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the DAS28 (k=0.70). In a second study, Aletaha et al. (53) reported good 
agreement (k=0.70) between the DAS28 and the CDAI. Two other studies (15, 
69) investigated agreement between the measures when classifying patients in 
lower disease levels. One study (69) an observational cohort of 621 patients, 
reported moderate to good agreement for DAS28 and SDAI or CDAI (k=0.63 and 
0.58, respectively, P<0.0001) when classifying patients in remission. The study 
found significantly more patients in DAS28 remission had CDAI values in low 
disease activity rather then in remission and similar results were observed for the 
SDAI and the DAS28. This study also reported residual swollen joints, a major 
determinant of joint destruction (73, 74) were seen in 13% of patients in DAS28 
remission compared to only 5% of patients in SDAI and CDAI remission. Based 
on the results of this study, the SDAI and CDAI are the more stringent measures 
compared to the DAS28 when classifying patients in remission. In a second 
study (15), an observational cohort of 200 early RA patients, the agreement 
between classifications by the DAS28, SDAI and CDAI cut points for minimal 
disease activity (MDA) were good (k= 0.68, k= 0.67) and the agreement for 
patients in remission when classifying by the DAS28, SDAI and CDAI was 
moderate (k= 0.48, k= 0.52).  
Two studies (66, 70) compared the abilities of the SDAI and the CDAI to 
predict physician responses by calculating the area under the curve (AUC) using 
receiver operating characteristic (ROC) curve analysis (75) (Table 1.8).  One 
study (70) reported the DAS28 had superior discriminative ability (AUC=0.840) 
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when compared to the SDAI and the CDAI.  The second study (66) reported that 
the SDAI was superior to the DAS28 (AUC=0.923). Even though the study 
results differed, the area under the curves for the three indices ranged from 
0.923 to 0.821, indicating that each index is highly predictive of a change in 
therapy.  
In five publications (16, 47, 62, 67, 71) various other methods to assess 
the categorization ability of the SDAI and the CDAI were used (Table 1.9). Three 
of the five publications (47, 67, 71) used the old SDAI cut points, and reported 
differences in the categorizations of patients by the EULAR and the SDAI. In the 
first study (47), the distributions of the disease activity categories were not 
normally distributed, and a Wilcoxon’s rank test was used to compare the 
categories. A highly significant difference was reported (Z=-13.078, p<0.0001) 
between the categories. The limit for the lower disease activity level of the SDAI 
was reduced from 20 to 10 and the data was reanalyzed.  After the data was 
reanalyzed, insignificant differences between the EULAR and the SDAI scores 
were found (p=0.07, Wilcoxon’s rank test). The second study (71), reported a 
higher proportion of patients was classified as having low disease activity by the 
SDAI criteria then the EULAR criteria.  A third study (67), compared the 
categorization abilities of the SDAI with the EULAR and ACR response criteria 
sets. The study grouped the EULAR moderate and major responders into a 
EULAR “overall” group and grouped the SDAI minor and major responders into a 
SDAI “overall” group. All of those that showed an ACR 20% response were found 
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in the EULAR and SDAI overall groups, but only moderate agreement between 
the ACR50% response levels and the EULAR good level and the SDAI major 
level was reported.   Two studies (16, 62) used the new SDAI cut points to 
categorize patients. One study (62) determined the ACR responder status of an 
inception cohort of patients and then categorized them as either responders or 
nonresponders, according to the ACR criteria. The proportion of patients that 
were classified according to the SDAI and DAS28 were then compared in the 
responder and nonresponder groups. At remission, the DAS28 classified more 
responders then the SDAI (34.9% v. 23.8%). But at high disease activity level, 
the classifications of the two indices were identical. A second study (16), using 
an observational cohort of early RA patients, reported on the degree of 
agreement between the measures to classify patient response utilizing EULAR 
criteria. In this study the DAS was used as the referent criterion and percent 
agreements were calculated. The percent agreements for the DAS with the SDAI 
and CDAI were 80%, and 74.4%, respectively. The data were re-analyzed using 
the DAS28 as the referent criterion and the percent agreements with the SDAI 
and CDAI were 73% and 74%, respectively.   
 
Responsiveness: 
  The ability of a measure to detect important changes over time in 
response to treatment was assessed for the SDAI and the CDAI in two studies 
(16, 53).  Both studies measured response with the ACR improvement criteria. In 
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one study (53), the average change in the SDAI and the CDAI where found to be 
greater in patients with a higher ACR improvement. A second study (16), using 
an observational cohort of 200 early RA patients found that the SDAI and the 
CDAI were both able to detect a statistically significant difference between no 
ACR response at baseline and an ACR 20/50/70 response at follow-up as well as 
between ACR50 and ACR70. However, a significant difference was not detected 
by the measures between ACR20 and ACR50 responders. 
 
(5) Discussion 
 
With advances in treatment modalities, accurate measurement of disease 
activity and response in individual patients in standard care is an important issue. 
In the present review, 12 published reports evaluated the measurement 
properties of two new disease activity indices, the SDAI and the CDAI to 
determine validity and reliability of the measures.     
  Evidence to support the concurrent validity of the SDAI and CDAI was 
found by this review. The level of correlation between the measures and DAS28 
was excellent in both observational cohorts that are representative of clinical 
practice and in RCTs, which are highly selected populations with higher disease 
severity, further supporting the generalizability of the concurrent validities of the 
SDAI and CDAI.  Recent questions have been raised about the appropriateness 
of the DAS28 as a measure of individual patients. A recent study (76) reported 
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that the DAS28 and the SDAI may not be appropriate measures of disease 
activity and response when assessing individual patients since both exclude the 
feet in their computations. The feet are often more involved then the hands and 
wrists especially in early RA (77).  A recent study (78) refuted these findings and 
reported that while the assessment of feet is an important part of the clinical 
evaluation of patients, reduced joint counts used in the DAS28 and SDAI are 
appropriate and valid for disease activity assessment.  Because all but one of the 
12 studies in this review used the DAS28 as a referent measure when assessing 
both the SDAI and CDAI, uncertainty about the appropriateness of the DAS28 as 
a measure of individual patients has serious implications with respect to the 
results of the studies included in this review. Further research is needed to 
resolve this issue.       
Little evidence was found to support the predictive or construct validities of 
the measures. Both of these validities are more informative then concurrent 
validity because they are associated with the ‘real’ situation in which the measure 
will be used. Two studies reported moderate correlations between the SDAI or 
CDAI when compared with the HAQ and radiographic progression. Because the 
correlations are only moderate and indicate variability between the measures, it 
is not possible to make very accurate predictions for individual patients of future 
functional capacity and radiographic progression using the SDAI or CDAI.  
Further studies in different populations should be conducted to further examine 
their validity.  
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Four studies assessed the discriminant validity of the measures when 
differentiating severity level between individual patients. The ability to accurately 
classify patients in lower disease levels especially in remission is an important 
issue in standard care. Differences in agreement between the SDAI, and CDAI 
with the DAS28 were found when classifying individual patients in remission. In 
addition, one study found that 13% of patients classified in DAS28 remission had 
more residual joint counts, a major determinant of joint destruction, compared to 
5% of patients in SDAI and CDAI remission.  This supports results found in a 
recent study (79) where patients that met DAS28 remission still exhibited 
synovitis after being assessed by MRI or ultrasound. It has also been shown that 
patients in DAS28 still exhibit synovitis in clinical examination (62, 80). Thus, the 
SDAI and CDAI appear to be the most specific measures compared to the 
DAS28 when classifying patients in remission since minimal residual joint counts 
were observed in SDAI or CDAI remission. When determining treatment 
decisions of individual patients based on classification into disease activity levels, 
the divergence between the discriminant ability of the DAS28, and the SDAI or 
CDAI should be considered.   
Several studies compared the classification of patient groups by the SDAI 
and CDAI with the HAQ score or radiographic progression. Two studies found 
that groups of patients in remission when classified by the SDAI and CDAI had 
low median HAQ scores. Two studies reported similar results when comparing 
radiographic progression to the SDAI and the CDAI patient groupings. Thus, at 
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the group level, the SDAI and CDAI appear to accurately discriminate groups of 
patients when compared to the HAQ and radiographic scores. However, whether 
individual patients classified by the SDAI and CDAI in remission would have low 
HAQ or radiographic progression has not been proven by these analyses and 
prediction of these future outcomes based on classification into disease severity 
levels cannot be made.      
In two studies, areas under the curve (AUC), from receiver operating 
characteristic (ROC) curve analysis were calculated to determine the ability of 
the SDAI and CDAI to predict physician response. Both measure had high AUCs 
indicating that they are highly predictive of a change in therapy. Additional 
studies should be performed to confirm these results.  
The SDAI and CDAI have met some of the criteria set forth by OMERACT 
but measurement of response to treatment and disease severity is complex and 
many issues remain to be determined. First, few studies assessed the 
performance of the CDAI and thus further validation of the measure, especially 
evidence to support the predictive and constructive validities using large 
observational cohorts is needed. In addition, consensus about the proposed 
CDAI cut points and criteria to reflect important clinical changes must be 
determined for use in future studies. Second, many of the studies included in this 
review were performed before the SDAI cut points were redefined. Only four 
studies were found that used the new SDAI cut points but although agreement 
between the ability to discriminate between patient groups of different functional 
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status and radiographic progression were not impacted, differences were seen 
between the classifications of the SDAI with the EULAR criteria depending on 
which cut points were used. Additional studies should be done to further validate 
the new SDAI criteria. Third, given that new treatment advances may help many 
patients attain sustained minimal disease activity or remission, it was surprising 
that only four studies were found that evaluated the performance of the 
measures in lower disease levels. Since differences were found in the 
discriminant ability of the measures, and none of the studies that determined 
correlations between the measures investigated whether the measures were 
correlated at lower disease levels, more studies are needed to determine which 
measure is most accurate and valid in low disease levels. Fourth, 
responsiveness of the SDAI and CDAI was evaluated in only two studies and 
both studies reported that the measures were able to differentiate between 
response categories. More studies are needed to confirm these results. Lastly, 
few studies evaluated the performance of the measures when assessing 
individual patients. Accurate assessment of disease activity in patient groups 
differs from the assessment of individual patients due to differences in 
comorbidities, treatment, and other characteristics of the individual patient. 
Additional studies need to evaluate the performance of the measures in 
individual patients.  
In conclusion, this review highlights the complexity involved in determining 
appropriate and accurate measures of disease activity and response in standard 
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care. Evidence for concurrent validity of the SDAI and CDAI was found, and 
some evidence for responsiveness and discriminant validity when differentiating 
patients in different disease states and predicting change in treatment. However, 
divergence between the measures was reported when classifying individual 
patients at lower disease severity. With advances in treatments, many patients 
may now realize low disease activity and remission, and it will be important to 
have measures that are valid clinical assessment tools at these levels. This 
review showed little evidence to support the predictive and construct validities of 
the SDAI and CDAI. Studies compared patient groupings to the HAQ and 
radiographic progression but not individual patient classifications. More studies 
need to be done to evaluate the SDAI and CDAI as measures of individual 
patients and as accurate measures when used in remission before they can be 
recommended as sole quantitative measures in standard care.  
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Table 1.4 Search Strategy  
 
                                                    
 
 
 
 
 
 
 
 
 
 
  
A  
 
B C 
 
D 
 
Rheumatoid arthritis  
OR 
Arthritis 
OR 
Rheumatic diseases  
 
 
Disease activity indices 
OR 
Disease Activity Index 
OR  
Composite Index 
OR  
Composite indices 
 
 
ACRa 
OR 
ACR20b  
OR  
ACR50c 
OR  
ACR70d 
OR 
ACR90e 
OR 
EULARf 
OR 
DASg 
OR 
DAS28h 
 
 
SDAIi 
OR 
CDAIj 
 
aAmerican College of Rheumatology(ACR)improvement criteria; bAmerican 
College of Rheumatology 20% improvement criteria(ACR20); c American College 
of Rheumatology 50% (ACR50)improvement criteria; d American College of 
Rheumatology 70% (ACR70)improvement; eAmerican College of Rheumatology 
90% (ACR90)improvement; fEuropean League Against 
Rheumatism(EULAR)response criteria; gDisease Activity Index; hDisease Activity 
Index with 28 joint count(DAS28); iSimplified disease Activity Index; jClinical 
Disease Activity Index. 
 
 
A + B = #1 
=1587 
#1 + C= #2 
=342 
#2 + D =#3 
=17 
After abstracts 
reviewed= 12 
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Table 1.5 Measurement properties of disease outcome measures  
 
Property  Description 
 
Truth (validity)  
 
The ability of a measure to truly measure what it intends 
to measure. It includes the following domains:  
           
          Face Validity 
 
The aggregation of the individual components in an 
index appears sensible.   
           
          Content Validity 
 
The choice and importance given to the components of 
the index and that sample multiple domains in RA.    
          
          Criterion Validity 
          Subtypes: Concurrent  
                           Predictive 
 
The extent that a measure  
  - correlates with a ‘gold standard’ 
  - predicts future outcome of disease (i.e.   
     functional disability)  
          
         Construct Validity 
 
The ability of a measure to agree with the final outcome 
of the disease such as radiographic progression    
 
Discrimination 
 
The ability of a measure to differentiate between 
different disease states at one time (classification) or at 
different times (to measure change). It includes the 
following domains:  
           
          Reliability  
 
The ability of the measure to yield the same results on 
repeated applications.  
           
          Responsiveness 
 
The ability of a measure to detect important changes in 
the outcome after treatment has been initiated.  
 
Feasibility 
 
The ability of a measure to be easily applied in the 
setting of which it is intended.  
 
Information from Bombardier and Tugwell (81) and Boers (82)
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Table 1.6 Concurrent and predictive validities of the composite indices. 
Study design- 1: Observational, 2: Inception, 3: Longitudinal, 4: RCT  
aDisease Activity Index with 28 joint count(DAS28); bSimplified Disease Activity Index; cClinical Simplified Disease Activity Index;  
dHealth Assessment Questionnaire 
*Significant correlations at p<0.0001 
†n=720 for correlations with HAQ 
±n=104 for correlations with HAQ 
Author  
(Ref. no.) 
Study 
Design 
Sample 
Size 
Sex (% 
female) 
 
Correlations with DAS28a 
 
 
Correlations with HAQd 
 
SDAIb CDAIc SDAIb CDAIc 
 
SMOLEN (54) 
 
 
4 
 
399 
 
76.9 
 
At baseline:     At 6 months: 
rtrial1=0.91*      rtrial1=0.93* 
rtrial2=0.91*      rtrial2=0.91* 
rtrial3=0.80*      rtrail3=0.91* 
 
  
At baseline:     At 6 
months:  
rtrial1=0.46*       rtrial1=0.63* 
rtrial2=0.44*       rtrial2=0.66* 
rtrial3=0.36*       rtrial3=0.53* 
 
 
rtrial1=0.56* 
rtrial2=0.56* 
rtrial3=0.47* 
ALETAHA (53) 1 279 79.9 r=0.91    
 
r=0.89 
 
r=0.46 
 
r=0.45 
 
2 105 65.2 r=0.90  r=0.89 
 
r=0.31 
 
r=0.30 
 
LEEB (47) 
 
1 767† 79.9 r=0.89    
3 105± 65.2 r1=0.89  r2=0.85  r3=0.84    
 
 
VANDER 
CRUYSSEN 
(66) 
 
 
4 
 
 
1242 
 
 
65 
 
 
r=0.91 
 
 
r=0.89 
  
 
ALETAHA (62) 
 
 
1 
 
115 
 
82.6 
 
r= 0.91  
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Table 1.7 Agreement between the categorization ability of the composite indices*.   
 
Author (ref. no.) Study 
Design 
Sample 
Size 
Sex (% 
female) 
 
SDAIb 
Cut 
Points 
 
DAS28a v. SDAIb 
 
DAS28a v. CDAIc 
 
ALETAHA (62) 
 
 
1 
 
767 
 
79.9 
 
New 
 
κ=0.70 
- 
ALETAHA (53) 1 767 79.9 N/A - κ=0.70 
 
MIERAU (69) 
 
1 
 
621 
 
78.1 
 
New 
 
In remission:  
κ=0.63 * 
 
In remission:  
κ=0.58* 
 
KHANNA (15) 
 
1 
 
200 
  
New 
 
In remission: 
κ =0.48 
In low disease activity:  
κ=0.68 
 
In remission: 
κ =0.52 
In low disease activity: 
κ =0.67  
* Degree of agreement indicated by kappa values from Altman (72): <0.2 = poor agreement; 0.2-0.4 = fair 
agreement; >0.4-0.6 = moderate agreement; >0.6-0.8 = good agreement; >0.8-1.0 = excellent agreement.   
Study design- 1: Observational, 2: Inception, 3: Longitudinal, 4: RCT  
aDisease Activity Index with 28 joint count(DAS28); bSimplified Disease Activity Index;  
cClinical Simplified Disease Activity Index;  
* p=0.0001 
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Table 1.8 Area under the curve of the composite indices.   
Author (ref. no.) Study design 
Sample 
Size DAS28
a SDAIb CDAIc 
 
VANDER CRUYSSEN (66) 
 
4 
 
511 
 
AUC=0.840 
 
AUC=0.824 
 
AUC=0.821 
 
SOUBRIER (70) 1 204 AUC=0.872 AUC=0.923  
  
Study design- 1: Observational, 2: Inception, 3: Longitudinal, 4: RCT  
AUC- Area under the curve 
aDisease Activity Index with 28 joint count(DAS28); bSimplified Disease Activity Index;  
cClinical Simplified Disease Activity Index;  
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Table 1.9 Classification of patients by the composite indices  
Author (ref. no.) Study Design 
Sample 
Size 
Sex  
(% 
female) 
SDAIb 
Cut 
Points 
Classifications Significance 
 
LEEB (47) 
 
 
1  
 
 
399 
 
76.9 
 
Old 
 
SDAIb: 
74.4% low 
21.1% moderate 
4.3% high 
 
EULARd: 
42.9% low 
41.4% moderate 
15.8% high 
 
p<0.0001 
 
LEEB (71) 
 
 
1 
 
 
207 
 
75.8 
 
Old 
 
SDAIb:  
95%-low 
2.5% -medium 
2.5%-high 
 
EULARd: 
68%-low 
30% -medium 
2%-high 
- 
 
GÜLFE (67)  
 
 
1 
  
 
184 
 
75 
 
Old 
 
SDAIb:  
100%-at ACR20% level* 
61%-at ACR50% level† 
 
EULARd: 
100% at ACR20% level* 
61% at ACR50% level† 
 
No p-value 
reported 
 
ALETAHA (62) 
 
 
2 
 
91 
 
- 
 
New 
 
SDAIb: 
In remission:  
ACR20 responders- 23.8% 
Non-7.1% 
 
In high disease activity:  
ACR20 responders- 1.6% 
Non-21.4% 
 
DAS28a:  
In remission:  
ACR20 responders-34.9% 
Non-10.9% 
 
In high disease activity: 
ACR20 responders-1.6% 
Non-21.4% 
p<0.01  
 
RANGANATH 
(16) 
 
1  
 
223 
 
78.5 
 
New 
 
DASe v. SDAIb:  80%** 
DAS28a v. SDAIb: 73%** 
 
 
DASe v. CDAIc: 74%** 
DAS28a v. CDAIc: 74%**   
 
- 
Study design- 1: Observational, 2: Inception, 3: Longitudinal, 4: RCT  
*SDAI “overall” and EULAR “overall” response levels compared to ACR20% responders. 
†SDAI “major” and EULAR “good” response levels compared to ACR20% responders.  
** Per cent agreements ; aDisease Activity Index with 28 joint count(DAS28); bSimplified Disease Activity Index; cClinical Simplified 
Disease Activity Index; dEuropean League Against Rheumatology response criteria (EULAR);  
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1.5   Summary 
For new treatment modalities such as DMARDs to be optimally effective in 
decreasing joint damage and destruction, clinical management of RA must focus 
on feasible and valid measures to facilitate the consistent monitoring of disease 
activity and response to treatment. In addition, feasible measures of disease 
activity are also needed in epidemiological research using data from large 
observational registries, to prevent the exclusion of patients from research 
studies due to missing disease activity scores.   
Several studies have evaluated two new simplified composite measures, 
the CDAI and SDAI, and reported on their validity as measures of clinical disease 
activity (15, 16, 43, 45, 47, 66, 69, 70, 83, 84). Since studies assessing the 
performance of the composite measures using large sample sizes are lacking, a 
recent study by Greenburg et al (45) using a large observational cohort, 
examined the measurement agreement between the CDAI, SDAI and DAS28. 
New cutoff values based on this sample were determined for the CDAI and the 
SDAI and then compared with the DAS28.  The study found the performance of 
the CDAI and the SDAI comparable with the DAS28 in this population, but 
differences between the measures remain (18).  To further examine the validity 
of the CDAI as a clinical care measure to monitor treatment response and guide 
treatment decisions, in the second chapter of my thesis, I will present findings 
from a study where the association of the CDAI with a rheumatologist’s decision 
to change therapy was evaluated. In addition, little previous research has been 
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done to examine correlates that might influence physician prescribing behavior. 
Thus, factors, including patient, clinic and physician characteristics, were 
investigated as predictors of physician’s decision to change therapy using a 
multi-level modeling strategy.     
Acute phase reactants, ESR and CRP have long been used in clinical 
care as measures of disease activity. However, variability in the clinical 
measurement of these two laboratory values has been reported (50, 51). In 
addition, a recent study (85) raised concerns about the appropriateness of the 
ESR and CRP as measures of disease activity. Thus, in the third chapter of my 
thesis, I will present findings from a study where correlates influencing physician 
clinic decision-making regarding measurement of the ESR and CRP are 
identified using a multi-level modeling strategy. Also the frequency of ESR and 
CRP testing is described and the variability in measurement of ESR and CRP is 
quantified.   
Treatment recommendations published by the ACR in 2008 recommend 
measurement of disease activity to guide treatment decisions (9). However, two 
composite measures of disease activity currently available for use in clinical care, 
the DAS28 and SDAI, cannot be computed at some clinical encounters due to 
missing laboratory values (i.e. ESR or CRP). In epidemiological research, 
patients with missing values of disease activity due to missing laboratory values 
are often excluded from analyses. In an attempt to facilitate the inclusion of 
patients in epidemiological research and to improve the clinical management of 
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RA, in the fourth chapter of this thesis, I will present findings from a study where I 
developed and validated a new measure of disease activity and response, the 
modified DAS28 (mDAS28). A model was developed that predicted factors 
associated with ESR. These significant factors were then imputed into the 
DAS28 formula in place of the ESR value. The performance of this new measure 
was then evaluated by comparing its performance with the DAS28, CDAI and 
SDAI.  As of writing this thesis, the study described in this chapter is under 
review by the Journal of Rheumatology. The three studies presented in my 
dissertation research have been reviewed and approved by the University of 
Massachusetts Institutional Review Board.  
In conclusion, the work detailed in this thesis furthers the knowledge of 
measurement of disease activity in rheumatoid arthritis by determining the 
reliability, validity and utility of disease activity measures for use in standard 
clinical care settings. By validating measures of disease activity, individual 
patient response to effective therapeutic agents can be consistently monitored to 
impede further joint damage and destruction and ultimately improve patient 
outcomes.   Results from analyses in the identification of correlates, which might 
influence physician practice behaviors, are also presented.  
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CHAPTER II  
 
Use of CDAI and DAS28 to Inform Clinical Decision-Making  
In Patients with Rheumatoid Arthritis:  
Do They Reflect Physician Prescribing Behavior?  
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2.1 Abstract 
 
Objective: To examine the association of composite disease activity indices, 
CDAI and DAS28, with a physician’s decision to change disease-modifying 
antirheumatic drug (DMARD) therapy in patients with rheumatoid arthritis (RA). 
Also to identify patient, physician and practice characteristics associated with 
change in DMARD therapy.  
 
Methods:  Data were obtained from a multi-site, longitudinal, observational 
registry, the CORRONA registry.  Initiators of a DMARD were identified and a 
change in therapy was assessed at each follow up visit. The association of 
disease activity indices and change in DMARD therapy was examined in 4,955 
follow up visits using multi-level mixed multivariable models.  To assess the 
diagnostic accuracy of the CDAI and DAS28 to discriminate a physician’s 
decision to change DMARD therapy, areas under receiver operating 
characteristic (ROC) curves were employed and the predictive positive value was 
calculated.   
 
Results:  4,955 follow-up visits from 1627 RA patients seen by 124 physicians at 
64 clinics were eligible for analysis. Of the 4,955 follow-up visits, 14.3% (n=709) 
had a change in DMARD therapy with 42% had an escalation and 48% had a 
discontinuation. In separate models, the CDAI (OR=1.58; 95% CI: 1.42,1.76) and 
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DAS28 (OR=1.54; 95% CI: 1.35, 1,74) were both significantly associated with 
change in DMARD therapy after controlling for visit-, patient-, physician, and 
clinic-level characteristics. However, a change in CDAI core was not significantly 
related. Other factors significantly associated with change in DMARD therapy 
included: initiation of a nonbiologic DMARD (OR=2.67; 95% CI: 1.78, 4.00), 
number of prior prescribed DMARDs (OR=1.69; 95% CI: 1.47, 1.95), patient age 
(OR=0.99; 95% CI: 0.98-1.01), duration of disease (OR=0.66; 95% CI: 
0.58,0.75), currently employed (OR=1.66; 95% CI: 1.10,2.49), physician age 
(OR=0.97; 95% CI: 0.95-1.00) and academic clinic (OR=1.92; 95% CI: 
1.08,3.40). The CDAI and the DAS28 were not strong predictors of a change in 
DMARD therapy as determined from area under the receiver operating 
characteristic curve analysis (AUC of 0.69 and 0.72, respectively).   The effect of 
patient characteristics on change in DMARD therapy was substantial.  
 
Conclusion:  A physician’s decision to change DMARD therapy was based in 
part but not completely on disease activity. The CDAI and DAS28 were not 
strong discriminators of a change in DMARD therapy and should not be used to 
guide treatment decisions in a clinic setting.    
 
Key words: Rheumatoid arthritis, Clinical Disease Activity Index, Disease 
Activity Score, Multi-level Mixed models, Receiver operating characteristic (ROC) 
curves, Discriminating ability  
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2.2 Introduction 
 
Rheumatoid arthritis (RA) is a complex disease with a wide array of 
disease manifestations causing disease management to be difficult (1, 2). 
Previous treatment recommendations published in 2002 (3) by the American 
College of Rheumatology (ACR) focused on the use of nonbiologic disease-
modifying antirheumatic drugs (DMARDs). In 2008, the ACR recently updated 
their recommendations, to address the rising rate of biologic DMARD use and 
suggested aggressive treatment with DMARDs to attenuate the risk for joint 
destruction and resulting disability (4).   
Little research has been done to determine whether physicians are 
adhering to these treatment recommendations.  Physician prescribing behavior 
may be influenced by many variables such as other physician practice behaviors, 
financial incentives, restrictions on treatments, factors unique to practice settings, 
cost and insurance, individual physician characteristics and individual patient 
characteristics, but specific factors have not been illuminated in the literature (5-
8). 
To facilitate physician clinical decision-making, the ACR has 
recommended several clinical factors to consider when making a therapy 
change: disease duration, prognostic factors and disease activity assessment 
(4).  To assess disease activity, many individual measures and composite indices 
are available (9).  One recent RCT, the TICORA study (10)) demonstrated that 
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aggressive therapy and consistent monitoring of disease activity with a 
composite index, the disease activity score (DAS) (11, 12), resulted in improved 
outcomes. Composite measures such as the clinical disease activity index 
(CDAI) (13) and the disease activity score with 28 joint count (DAS28) (14), if 
able to evaluate the effect of DMARD therapy and remaining disease activity in 
daily practice could be used to guide treatment and ultimately improve disease 
outcome. While validated in several studies (15-30), the ability of the CDAI and 
DAS28 to guide treatment decisions, to the best of my knowledge, has not been 
previously examined.   
Using data from a large, multi-site, observational registry, we evaluated 
whether a clinical decision by a physician to change DMARD therapy could be 
reflected by the CDAI or DAS28. We also sought to evaluate the effect on RA 
management of clinic, physician and patient-level characteristics. In addition, the 
discriminative ability of both measures to determine treatment change was 
evaluated by calculating the predictive probability value. Areas under the receiver 
operating characteristic curves (AUC) (31-34) were calculated to assess the fit of 
the models and the diagnostic ability of the measures.  
     
2.3 Methods 
 
 
Data Source  
Data for the analysis were from a large, multi-site, observational registry, 
the Consortium of Rheumatology Researchers of North America (CORRONA) 
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(35). The CORRONA registry contained information for more than 17,000 
patients with RA, 113 rheumatology practices, and 272 rheumatologists in the 
United States. Information was collected on patient and physician demographics, 
disease activity and severity, quality of life measures, medical comorbidities, and 
use of DMARD drug therapy. The data are obtained from patients and their 
treating rheumatologist using study questionnaires.  Follow-up exam visits are 
scheduled at three month intervals and completed during routine clinical 
encounters.   
 
Study Sample 
Subjects who had RA and had at least one visit where a DMARD had 
been newly prescribed during the study period between October 1, 2001 and 
November 1, 2008 were identified (n=3,172).  Since some of these 3,172 patients 
had switched DMARD therapy and initiated another DMARD at different visits, 
they had more than one visit with an initiation.  Thus, there were a total of 6,335 
initiation visits. The baseline visit was defined as the visit where a DMARD was 
first initiated. DMARD initiations that occurred between two scheduled visits, and 
had a prior visit within 4 months of the initiation, were included in the sample. 
Information from the prior visit was used as the baseline visit. A 4-month interval 
was decided upon because most DMARD therapies do not show an effect until 3-
6 months after initiation. Patient and physician information from the prior visit was 
utilized as the baseline visit. A total of 2,352 initiation visits were excluded 
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because they occurred between two visits and had a prior visit more than 4 
months of the initiation, leaving 3,983 visits with an initiation (baseline).  A 
baseline visit where an initiation had occurred had to have at least one follow up 
visit to be included in the sample. A total of 716 initiation visits were excluded 
from further analysis because they did not have at least one follow up visit, 
leaving 3267 initiation visits. The initiation baseline visit and its accompanying 
follow up visits comprised an “initiation segment “.  An additional 211 initiation 
segments or 1356 visits were excluded due to missing CDAI scores at the 
baseline visit leaving 3,056 initiation segments.    
In the analysis, DMARD initiators were followed over time until the 
outcome, change in DMARD therapy (defined in next section), occurred at a 
follow up visit or if no change in DMARD therapy occurred during the initiation 
segment, then until the last follow up visit of the initiation segment.  If a change in 
DMARD therapy occurred at a follow up visit, these follow up visits along with 
any follow up visits in an initiation segment that occurred prior to the change in 
DMARD therapy were included in the sample. Follow up visits where a change in 
DMARD therapy occurred prior (or between) the visit, were excluded from the 
sample because patient and physician information was not collected between 
regular visits.  Therefore, of the remaining 3056 initiation segments, 1429 
initiation segments were excluded from the analysis because a change in therapy 
occurred between visits.  
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The final sample contained 4,955 follow up visits within 1627 initiation 
segments. A sensitivity analysis was done to test any differences between the 
excluded visits and the ones included. The institutional review board of the 
University of Massachusetts Medical School approved the study. Since the study 
was a secondary analysis of existing data, the need for informed consent was 
waived.   
 
Outcomes of interest    
The primary outcome of interest was the physician’s decision to change 
DMARD therapy and was defined as any of the following having occurred at a 
follow up visit: (a). an addition of DMARD, (b). a discontinuation of baseline 
DMARD, and (c). a discontinuation of baseline DMARD and new DMARD added. 
The outcome was operationalized as a dichotomous variable, coded as ‘0’ for no 
change and ‘1’ for change (either a-c above). Individual components “a” and “b” 
(above) were also examined as separate outcomes in subsequent analysis and 
operationalized as dichotomous variables. Preliminary data analysis revealed 
that component “c” occurred in only 18 follow up visits. Thus, due to this low 
amount of occurrences, component “c” was not examined as a separate outcome 
variable. DMARD medications included in the analysis were 6 biologics: 
etanercept, adalimumab, anakinra, abatacept, infliximab, rituximab, and 7 
nonbiologics: methotreexate, leflunomide, sulfasalazine, cyclosporine, 
azathioprine, hydroxychoroquine, and minocycline.    
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Independent variables 
Data were organized into four levels to reflect the natural hierarchy of the 
data structure: visit-, patient-, physician- and clinic-level characteristics. The 
study utilized multi-level logistic regression mixed models to account for the 
correlation between the observations (visits), and the clustering of the data at the 
patient, physician and clinic levels. Multi-level modeling allows the simultaneous 
appraisal of group- and individual-level factors on individual-level outcomes (36).  
In the study sample, 11% of the clinics and 29% of the physicians reported no 
changes made in DMARD therapy. Thus we knew a priori that the physicians and 
clinics prescribing behavior varied widely. 
 
Visit-level factors: The effect of the CDAI on the prescription of DMARD therapy 
was assessed and the effect of its individual components, tender joint count 
(TJC; 0-28), swollen joint count (SJC; 0-28), physician’s global assessment of 
disease activity (PhGA; visual analog scale (VAS) 0-100 mm), and patient’s 
global assessment of disease activity (PGA; VAS 0-100 mm) were assessed in 
separate models. The effect of the DAS28 was assessed in separate sub-
analysis. The erythrocyte sedimentation rate (ESR; mm/h) was measured to 
calculate the DAS28.  The CDAI and DAS28 were calculated as previously 
described (11, 13). The effect of other disease activity variables on 
rheumatologist’s decision to change DMARD therapy included C-reactive protein 
(CRP; mg/l), modified health assessment questionnaire (mHAQ; 0-3) (37, 38), 
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patient assessment of pain (PAIN; VAS 0-100mm), RF positivity (RFpos), 
presence of erosions and joint narrowing, and morning stiffness. CDAI and 
DAS28 were calculated after data collection occurred so that the treating 
rheumatologist was not able to utilize either score to make a decision regarding a 
therapy change. Therapy characteristics at each follow up visit were also 
examined and included type of baseline initiation DMARD (i.e. biologic or 
nonbiologic), number of previous DMARDS prescribed, use of prednisone, and 
use of other therapies such as gastrointestinal medications, analgesics and 
antidepressants.  Calendar year was included as control variable since patients 
may have experienced different recommendations for therapy based on a 
particular year.   
Changes over time of the composite scores and disease activity variables 
were also considered.  Change scores were derived by calculating the change in 
disease activity from the baseline initiation visit to the next follow up visit. For 
example, if a patient had a follow up visit at 3 months and then at 6 months, the 
change scores were calculated as the difference between baseline and 3 months 
and then the difference between baseline and 6 months.   
 
Patient-level factors: included patient demographic variables: patient age at 
baseline which was operationalized as a continuous variable, patient race 
dichotomized as white or not white,  gender defined as male or female, education 
level which was dichotomized as having either completed college or no college, 
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marital status which was dichotomized into two levels, married or not married, 
employment status was dichotomized as either currently employed or not 
employed, and body mass index (BMI) was utilized as a continuous variable. 
Insurance status was assessed using two dichotomous variables: private 
insurance and public insurance. Public insurance include both Medicare and 
Medicaid and both insurance variables were dichotomized as “0” for no insurance 
and “1” for insurance. Duration of RA was a continuous variable. Comorbidities 
included seven conditions (hypertension, coronary artery disease, myocardial 
infarction, congestive heart failure, stroke, diabetes mellitus, and cancer) and 
were dichotomized into two levels, either having the disease or not.   
 
Physician-level factors:  Factors at the physician level included physician 
gender, defined as male or female, physician age and practice years.  The 
frequency of formulary restrictions and its influence on physician decisions was 
included in this level. This variable was operationalized as dichotomous with 
frequent formulary restrictions coded as 0 and infrequent coded as 1. Physicians 
also reported on the percentage of managed care in their practices. The variable 
was operationalized as a categorical variable with three categories:  <25%, 25-
50% or >50%.  A variable ”prescribing tendency” to assess the past tendency of 
an individual physician to prescribe DMARD therapy was derived. The variable 
was derived by averaging the number of previous DMARDs prescribed by a 
physician per their total number of patients.   
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Clinic-level factors: Clinic level variables included in model selection were:  
type of clinic (academic or private) and the geographic region in which the clinic 
was located. Geographic location was defined according to four regions: the 
Northeast, Midwest, South and the West according to the Geography Division of 
the U.S Census Bureau (39).   
 
Statistical analysis 
Descriptive statistics are presented as means and standard deviations 
(SD) for continuous data or as percentages for counts for the characteristics of 
the follow-up visits. In this study, the unit of analysis is the follow-up visit and the 
proportion of follow-up visits with a DMARD change was tabulated. To account 
for the correlation and clustering between levels of the data, univariate multi-level 
logistic mixed-modeling analysis was used to examine visit, patient, physician 
and clinic characteristics as potential predictors of a change in DMARD therapy. 
Variables that had univariate associations of P<0.10 and/or theoretically relevant 
were included in subsequent multi-level multivariate mixed-modeling. Correlation 
among the variables was examined using the variable inflation factor (VIF) (40). 
Variables found to have a VIF >2 were excluded from further modeling. The 
assumption of linearity of continuous variables with the endpoint was tested 
using two way plots with loess curves.  Variables not linear were transformed 
accordingly.  
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In the multilevel multivariable mixed models, concurrent values of the 
CDAI at each follow up visit and significant visit, patient, physician and practice-
site characteristics were evaluated as potential predictors of a change in DMARD 
therapy. This approach accounts for the clustering of visits within patients and 
patients within physicians. Using a single-level logistic regression model would 
ignore clustering of the patients in physicians, and physicians in clinics and may 
exaggerate the precision of the estimates. Each aspect of the primary outcome, 
escalation of DMARD therapy and discontinuation, were examined in separate 
analyses. The effect of the DAS28 on the physician’s decision to change therapy 
was estimated in a separate multi-level multivariate model.   The CDAI and 
DAS28 scores were standardized for ease of parameter interpretation in the 
models. Standardization of the CDAI occurred by dividing the CDAI score by 6.7, 
the value of a statistically significant change for the CDAI previously determined 
(27).The DAS28 was standardized by dividing the DAS28 score by 0.6, the value 
of a statistically significant change for the DAS28 previously determined (41). All 
continuous variables were centered and physician global assessment, patient 
global assessment, and patient pain scores were presented by decile to aid in 
interpretation of the results.   
 The fit and performance of the models to discriminate a change in 
DMARD therapy was assessed using areas under the receiver operating 
characteristic (ROC) curve analysis (32, 33). To build the models, the sample 
was divided into a random training (n=2499) and test (n=2456) datasets. The 
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models were developed in the training set and the test set was used to validate 
the model by making predictions from the data. The data predictions were 
created using ROC analysis and then compared with the observed data using the 
kappa statistic (42, 43). ROC curves were plotted for each model to determine 
the areas under the curves (AUC), sensitivity and specificity of each model. AUC 
values >0.75 indicate good discriminative ability (31). Cut points for the CDAI to 
delineate between change in DMARD therapy and no change were determined 
using ROC analysis and the Youden index (44, 45). The performance of the new 
cut point was compared to the actual observed change values using kappa 
statistics. Positive predictive value of the new test cut point was determined.  To 
quantify the proportion of residual variance attributable to variations between 
units of the 4 levels of hierarchy, random intercept variance, intra-cluster 
correlation coefficient (ICC) (46) and the median odds ratio (MOR) (46) were 
calculated. Residual variance is the proportion of unexplained variation in 
outcomes due to unmeasured characteristics at each of the 4 levels. All analyses 
were conducted using STATA, release 10.1 (47).     
 
 
2.4 Results 
 
 
A total of 4,955 follow up visits (level 1), were nested within 1,627 RA 
patients (level 2), and received care from 124 physicians (level 3), from 64 clinics 
(level 4). Baseline DMARD initiators (n=1627) had a mean CDAI score of 19.34, 
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had an average age of 56.8 (SD), had RA for an average of 9.92 years, 78% 
were female, most had insurance, and the number of past DMARDS was 1.68. 
Slightly more patients had initiated a biologic DMARD (n=873; 54%) at baseline, 
compared to a non-biologic (n=754; 46%).   
As shown in Table 2.1, a total of 4,955 follow up visits were eligible for 
analysis. Disease activity at the visit-level was moderate with a mean CDAI score 
of 11.8 and a mean DAS28 score of 3.28. Moderate disease also was reflected in 
other disease activity measures (Table 2.1).  Most patients were female and 
most were Caucasian. The mean age of patients was 58 years. The average 
percent of visits with comorbid conditions was 7% and the average number of 
previous DMARDS prescribed was 1.69.  The mean age of the 124 
rheumatologists was 56; 84% were men and had an average of 24 years in 
practice.  Most of the 64 practice sites were private (89%) compared to academic 
(11%).  Most clinics were located in the Northeast (52%) with only 4.5% in the 
West 
The proportion of follow-up visits with a change in DMARD therapy was 
709 (14.3%) compared to 4262 (85%) visits with no DMARD therapy change 
(Table 2.2).  Of these 709 visits, 483 (60%) had an escalation of DMARD 
therapy, 208 (30%) had a discontinuation of a baseline DMARD and 18 (7%) had 
a discontinuation of a baseline DMARD and another DMARD prescribed.  
In univariate analysis presented in Table 2.3, variables significantly 
associated with the decision to change DMARD therapy at a P≤0.10 level are 
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presented. Variables are grouped in the four hierarchical levels of the data listed 
earlier. Several quantitative disease activity measures were found to be 
significantly associated with a physician’s decision to change therapy and 
included the CDAI, DAS28, ESR, CRP, mHAQ, and pain score. The values of 
each quantitative score including the CDAI and DAS28 are concurrent values 
from each follow up visit. The CDAI and DAS28 were standardized and thus a 
change of 6.7 units in a CDAI score increases the probability by almost 60% that 
a physician will change DMARD therapy. Similarly for the DAS28, a change in 
0.6 in the DAS28 score increases the likelihood of a DMARD therapy change by 
almost 50%.  Change in CDAI score and a change in DAS28 score were also 
found significantly associated with a physician’s decision to change DMARD 
therapy. Univariate results for the second and third outcomes of interest, 
escalation of therapy and discontinuation were similar to the results for outcome 
one and are not presented.  
In adjusted analysis, the parameter estimates for all fixed effects of CDAI 
and the visit, patient, physician and clinic on the physician’s decision to change 
DMARD therapy are presented in Table 2.4. A change in 6.7 units of a CDAI 
score significantly increased the probability that the physician would change 
DMARD therapy by almost 60%. A baseline initiation of a nonbiologic DMARD 
and the number of past DMARDs prescribed at a clinical visit also significantly 
increased the probability that a physician would change DMARD therapy. A 
patient’s age and duration of disease were both inversely related to a change in 
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DMARD therapy. Patients who were currently employed were almost 70% likely 
to receive a change in DMARD therapy. As a physician aged, the probability of a 
change in DMARD was decreased. Academic clinics compared to private had 
almost a 2-fold increase in probability of changing DMARD therapy. A change in 
CDAI score was not found to be significantly related to a physician’s decision to 
change therapy after controlling for fixed and random effects (OR=1.01; 95% 
CI:0.92-1.11). In a separate adjusted analysis, the DAS28 was found to be 
significantly associated with the physician’s decision to change therapy 
(OR=1.54; 95% CI: 1.35, 1.74).   Multivariate analysis of the second and third 
outcomes, escalation and discontinuation of DMARD therapy showed similar 
results and are not shown.  
When assessing the fit of the CDAI model (Table 2.4), the full model 
including fixed and random effects performed well to discriminate physician 
decision to change DMARD therapy (AUC=0.96). The discriminatory ability of 
both the CDAI and DAS28 to delineate change in DMARD therapy was similar 
with an AUC of 0.69 for CDAI and 0.72 for DAS28. The discriminative ability of 
the CDAI was improved when random physician and patient effects were 
accounted for in the model (AUC= 0.91) but was weaker when not including 
random effects (0.69). Accounting for unobserved patient and physician random 
effects played a role in increasing the predictiveness of the CDAI.  The CDAI cut-
off value for change in DMARD therapy with the highest combination of 
specificity and sensitivity was 14.1. When the performance of the newly derived 
                                                                            
63
 
cut point was compared to actual physician behavior, analysis by kappa statistics 
showed moderate agreement. The positive predictive value of the CDAI was 41% 
and was calculated by taking into account the low prevalence of physician 
change in DMARD therapy in the sample population (14%).   
The proportion of the unexplained variation in the primary outcome due to 
unmeasured characteristics at each of the four levels of hierarchy was 
determined and is presented in Table 2.5. There was strong and significant effect 
of clustering found at the individual patient level. In model 1 (empty model), there 
was variation in the physicians’ decision to change DMARD therapy across 
physicians (τ=0.69) and across patients (τ=1.33). Yet, little variation was found 
across clinics (τ=1.8e-10). Intra-class correlation coefficients (ICC) for each level 
of data support these findings with 0%, 12.9% and 25%  variation in the change 
of DMARD therapy, attributed to clinic, physician and patient level factors, 
respectively. However, results from the final four level model (Table 2.5, Model 5) 
after accounting for residual variation at the visit-, patient-, physician- and clinic-
level factors, the effect was significantly attenuated at the patient level but still a 
significant effect. Median odds ratios (MOR), presented in table 5 for each of the 
models, confirmed that patient characteristics influenced the decision to change 
DMARD therapy. The high MOR values in all of the models at the patient level 
suggest that the patient heterogeneity in the decision to change DMARD therapy 
is substantial.  
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In other analyses, differences in disease activity over time and response 
scores were examined to discriminate the rheumatologist’s decision. Those 
analyses indicated that change variables seem to be less important than disease 
activity measured concurrently at a follow up visit to discriminate the 
rheumatologist decision.  
 
2.5 Discussion 
 
 
The aim of the present analysis was to evaluate whether a composite 
index such as the CDAI or DAS28 could discriminate the treating physician’s 
decision to change DMARD therapy in RA patients.  Using data from the large, 
multi-site longitudinal CORRONA registry, the results of the present study 
indicate that the CDAI and DAS28 both were significantly associated with change 
in DMARD therapy.  Yet, the CDAI and DAS28 were found to be poor predictors 
of change in DMARD therapy as indicated by a low AUC and PPV.   The 
discriminative power of the CDAI without controlling for random effects was much 
lower compared to the final model which included the random effects. Thus, 
based on these results, the CDAI and DAS28 would not be good discriminators 
of a change in DMARD therapy in the clinic.  
 Follow up visit characteristics that were found to be predictive of a 
decision to change DMARD therapy included an initiation of a nonbiologic 
DMARD at baseline and the number of past DMARDS prescribed at the follow up 
visit. With an initiation of a nonbiologic DMARD, results of the study indicated 
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that a physician would be almost 3 times more likely to change DMARD therapy. 
Biologic DMARD therapy has been found to be more effective then nonbiologics 
and ACR treatment recommendations do suggest aggressive DMARD therapy to 
prevent disease progression (4), factors which provide support for our results. 
The number of past DMARDs prescribed increased the likelihood of a change in 
DMARD therapy by almost 70%. Prior research has reported that frequent 
switching of DMARD therapy results in improved outcomes (48). This finding may 
indicate that physicians are switching DMARD therapy to achieve a treatment 
response.  
 Patient characteristics significantly predictive of a DMARD therapy change 
included patient age, disease duration and employment status. Patient age was 
inversely related to a change in therapy, a finding supported by previous 
research which found that older patients with RA receive less switches in 
DMARD therapy.  Also duration of disease was inversely related to change in 
DMARD therapy. Patients who were currently employed compared to those not 
employed had an almost 70% likelihood of receiving a DMARD therapy change. 
This finding could be due to differences in insurance coverage. Further research 
needs to be conducted to determine the reasons for this finding.  
 Only one physician characteristic was predictive of change in DMARD 
therapy. Physician age was inversely related to change in DMARD therapy with 
3% less chance of a therapy change for every year increase in physician age. 
This finding may be related to physician training and practice styles.  
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 Type of practice environment was found to influence DMARD therapy 
change with academic clinics strongly predictive of a change in DMARD therapy. 
Physicians at academic clinics may be involved in research efforts and, thus may 
be more likely to switch therapies. Patient populations that visit academic clinics 
may differ from those at private clinics and may change the prescribing 
tendencies of physicians. 
 Variation in the physicians’ decision to change DMARD therapy was found 
to be strongly influences by patient characteristics with little variation due to clinic 
or physicians. Thus interventions to improve adherence of physician prescribing 
of DMARDs should target patient levels characteristics and not the individual 
physician or clinic where little variation was found.              
 This study has several strengths. The data source utilized for the study is 
a large, observational cohort of patients with RA form across the United States. 
Thus the results from the study are generalizable throughout the U. S. Second, 
the study utilized a training dataset to develop the models and a test dataset to 
test the models for fit and discriminative ability which adds to the robustness of 
the results. Third, the study utilized a multi-level mixed effects modeling strategy 
to account for correlation between individual visits and clustering effects at each 
level of the data. The study is limited by not having data on several variables 
which could impact a rheumatologist’s decision-making process such as case-
mix of the patient population or quality assurance programs that had been 
implemented which may result in a loss of heterogeneity in the use of therapies 
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for patients. Since we did not have this information, we were unable to control for 
these differences between patients and clinics.         
   In summary, disease activity as measured by the CDAI and the DAS28 
was found to be significantly associated with a physician’s decision to change 
DMARD therapy. Change in disease activity over time was not found to be 
associated with a change in therapy. The CDAI and DAS28 were not found to be 
strong predictors of a change in therapy and thus based on these results should 
be used in clinic care to guide treatment decisions. To our knowledge, this is the 
first large scale study which demonstrated the association of the CDAI and 
DAS28 with physicians’ decision to change DMARD therapy. These results 
should be verified in further studies, but using the CDAI and the DAS28 in the 
clinical setting to guide treatment appears not to be warranted.    
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Table 2.1 Visit, patient, physician and clinic characteristics of follow up visits  
(n=4955)   
Characteristics N 
 
Mean (SD) 
 
Visit-level (n=4,955) 
 
CDAI, mean (SD) 
 
4728
 
11.82 (10.89)  
 
DAS28, mean (SD) 
 
1982
 
  3.28 (1.44)  
 
TJC, mean (SD) 
 
4935
 
  2.86 (5.02) 
 
SJC, mean (SD) 
 
4936
 
  4.24 (5.91) 
 
ESR, mean (SD) 
 
2078
 
22.08 (20.20) 
 
CRP, mean (SD) 
 
1688
 
  2.91 (8.09) 
 
PhGA, mean (SD) 
 
4948
 
18.17 (16.80) 
 
PGA, mean (SD) 
 
4747
 
29.67  (24.42) 
 
Pain, mean (SD) 
 
4812
 
31.26 (24.93) 
 
mHAQ, mean (SD) 
 
4847
 
  0.40 (0.45) 
 
Number of past DMARDs 
 
4955
 
  1.69 (1.67) 
 
Corticosteroids (%) 
 
4939
 
31.0 (0.42) 
 
Non-steroidal  (%) 
 
4955
 
59.0 (0.30) 
 
Antidepressants (%) 
 
4955
 
29.0 (0.45) 
 
Baseline DMARD initiation (n=1627) 
 
        
        Nonbiologic¥ 
 
754
 
1.35 (0.23) 
          
        Biologic*  
 
873
 
1.67 (0.34) 
 
Patient-level (n=1627) 
 
Age, mean (SD) 
 
4944
 
58.80 (12.54) 
 
Caucasian (%) 
 
4901
 
87.0 (0.34) 
 
Female (%) 
 
4955
 
76.0 (0.43) 
 
BMI (%) 
 
4926
 
29.3 (7.15) 
 
RA duration, yrs , mean (SD) 
 
4949
 
11.37 (9.61) 
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Currently working (%)  4955 43.0 (0.31) 
 
Private insurance (%)  
 
3851
 
78.0 (0.42) 
 
Comorbidities ± (%) 
 
4955
 
  7.0 (0.24) 
 
Physician-level (n=124) 
 
Male gender (%) 
 
4837
 
84.0 (0.37) 
 
Age, mean (SD) 
 
4674
 
56.2 (6.51) 
 
Years in practice, mean (SD) 
 
4777
 
24.5 (7.20) 
 
% of managed care 
 
     
     <25% 
 
1184
 
23.9 (0.43) 
     
       25-50 
 
1044
 
21.1 (0.41) 
     
      >50 
 
2493
 
50.3 (0.50) 
 
Formulary restrictions 
 
  
      Frequent 
 
2973
 
60.0 (0.49) 
  
      Infrequent 
 
1830
 
37.0 (0.48) 
 
Prescribing tendency 
 
4955
 
1.54 (1.01) 
 
Clinic-level (n=64) 
 
Academic, (%) 
 
4764
 
11.0 (0.32) 
 
Region, mean (SD) 
 
 
      Northeast 
 
2510
 
51.0 (0.50) 
 
      Midwest 
 
1450
 
29.26 (0.46) 
 
      South 
 
623
 
12.57 (0.33) 
 
      West 
 
217
 
  4.40 (0.20)  
CDAI- clinical disease activity index; DAS28-disease activity score with 28 joint count; TJC-tender 
joint count with 28 count; SJC-swollen joint count with 28 count;  ESR- ethrocyte sedimentation 
rate; CRP-C-reactive protein; PhGA-physician global assessment; PGA- patient global 
assessment; mHAQ-modified Health Assessment Questionnaire; BMI-body mass index; RA-
Rheumatoid arthritis 
 ±comorbidities includes hypertension, coronary artery disease, myocardial infarction, congestive 
heart failure, stroke, diabetes mellitus, and cancer. 
¥nonbiologics includes: methotreexate, leflunomide, sulfasalazine, cyclosporine, azathioprine, 
hydroxychoroquine, and minocycline    
*biologics includes: etanercept, adalimumab, anakinra, abatacept, infliximab, rituximab  
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Table 2.2 Proportions of changes in DMARD therapy at follow up visits (n=4,955) 
  
Changes in DMARD therapy   Number of changes  
 
Any DMARD change 
           
          709   
 
DMARD discontinuation 
           
          208   
 
DMARD addition    
           
          483   
 
DMARD Discontinuation and then addition  
           
            18 
 
No change 
         
        4262          
      DMARD- disease-modifying antirheumatic drug  
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Table 2.3 Univariate analysis of a rheumatologist’s decision to change DMARD 
therapy at a follow up visit (training dataset n=2499) 
CDAI- clinical disease activity index; DAS28-disease activity score with 28 joint 
count; ESR- erythrocyte sedimentation rate; CRP-C-reactive protein; mHAQ-
modified Health Assessment Questionnaire; BMI-body mass index 
±comorbidities includes hypertension, coronary artery disease, myocardial 
infarction, congestive    heart failure, stroke, diabetes mellitus, and cancer. 
¥nonbiologics includes: methotreexate, leflunomide, sulfasalazine, cyclosporine, 
azathioprine,  hydroxychoroquine, and minocycline    
Variable  Odds Ratio (95% 
CI) 
P Value 
Level 1 : Clinical encounter 
CDAI 1.59 (1.43-1.75) 0.00 
Change in CDAI 1.22 (1.13-1.31) 0.00 
DAS28 1.46 (1.44-1.47) 0.00 
Change in DAS28 1.14 (1.09-1.26) 0.00 
ESR 0.96 (0.94-0.98) 0.00 
CRP 0.94 (0.91-0.97) 0.00 
mHAQ 0.67 (0.53-0.95) 0.03 
Pain Score  1.11 (1.05-1.54) 0.05 
Nonbiologic baseline initiation¥ 2.54 (2.13-2.75) 0.00 
No. of past DMARDs 1.68 (1.54-1.85) 0.00 
Level 2: Patient  
Patient age 0.98 (0.97-0.99) 0.01 
Female  1.05 (0.99-1.10) 0.00 
White 0.84 (0.78-0.89) 0.03 
BMI 1.00 (0.99-1.004) 0.00 
Duration of disease 0.98 (0.95-0.990 0.00 
Currently employed 0.95 (0.91-0.99) 0.05 
Private insurance 1.05 (1.00-1.09) 0.06 
Comorbidities± 0.87 (0.58-0.76) 0.00 
Level 3: Physician  
Physician age 0.97 (0.97-0.98) 0.00 
Male  0.83 (0.78-0.88) 0.00 
Propensity to prescribes 1.52(1.24-1.65)  0.00 
Level 4: Clinic   
Academic  1.56 (1.23-1.76) 0.00 
Geographic region   
                       Northeast  1.00     
                       Midwest 1.34 (1.27-1.43) 0.02 
                       South 0.66 (0.62-0.71) 0.02 
                       West 1.09 (1.01-1.19) 0.01 
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Table 2.4 Multivariate analysis of visit, patient, physician and clinic variables 
associated with a DMARD change (training dataset n=2499)  
Variable   Odds Ratio (95% CI) 
 
P Value   
 
CDAI 
 
1.58  (1.42-1.76) 
 
0.00 
 
Nonbiologic baseline initiation¥ 
 
2.67 (1.78-4.00) 
 
0.00 
 
No. of past DMARDS 
 
1.69 (1.47-1.95) 
 
0.00 
 
Patient age 
 
0.99 (0.98-1.01) 
 
0.00 
 
Duration of disease 
 
0.66  0.58-0.75) 
 
0.03 
 
Currently employed 
 
1.66 (1.10-2.49) 
 
0.01 
 
Physician age  
 
0.97 (0.95-1.00) 
 
0.00 
 
Academic clinic  
 
1.92 (1.08-3.40) 
 
0.00  
DMARDs-disease modifying antirheumatic drugs; CDAI- clinical disease activity 
index;  
¥nonbiologics includes: methotrexate, leflunomide, sulfasalazine, cyclosporine, 
azathioprine, hydroxychoroquine, and minocycline    
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           Table 2.5 Sources of variation among rheumatologists to change a DMARD  
           (training dataset: n=2499) 
 
Measures of variation  Model 1
a Model 2b Model 3c 
 
Model 4d Model 5e 
 
Clinic level 
   
  Variance (SE) 
 
1.8e-10 (0.21) 
 
2.15 e-9 (0.12) 
 
3.68e-9 (0.36) 
 
7.07e-12 (0.33) 
 
9.22e-11 (0.18) 
 
   ICC (%) 
 
0.00 
 
0.00 
 
0.00 
 
0.00 
 
0.00 
 
   MOR 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
1.00 
 
Physician level 
 
  Variance (SE) 
 
0.69 (0.11) 
 
0.0001 (0.35) 
 
6.53e-9 (0.60) 
 
1.12e-11 (0.56) 
 
2.89e-11(0.27) 
 
  ICC (%) 
 
12.9 
 
0.00002 
 
0.00 
 
0.00 
 
0.00 
 
  MOR 
 
2.21 
 
1.01 
 
1.00 
 
1.00 
 
1.00 
 
Patient level 
 
  Variance (SE) 
 
1.33 (0.11) 
 
1.89 (0.71) 
 
9.26 (2.2) 
 
7.98 (2.30) 
 
1.87 (0.86) 
 
  ICC (%) 
 
25.0 
 
36.5 
 
74.0 
 
71.0 
 
36.0 
 
  MOR 
 
3.00 
 
3.71 
 
18.22 
 
14.8 
 
3.69  
           DMARD- disease-modifying antirheumatic drug; SE- standard error; ICC- intra-class correlation; MOR- median odds ratio  
                   a  Model 1 is the null model containing no predictor variables 
                   b Model 2 contains visit variables  
                   c Model 3 contains visit and patient-level variables  
                   d Model 4 contains visit, patient and physician-level variables  
                   e Model 5 contains visit, patient, physician and clinic-level variables 
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CHAPTER III 
 
Clinical Measurement of Erythrocyte Sedimentation Rate 
and C - reactive Protein in Patients with Rheumatoid Arthritis Is  
Not Associated with Disease Activity  
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3.1 Abstract 
 
Objective: To determine the frequency of erythrocyte sedimentation rate (ESR) 
and C-reactive protein (CRP) measurement, identify predictors of ESR and CRP 
measurement and quantify the variation among rheumatologists in their 
measurement.   
 
Methods: Frequency of ESR and CRP measurement was tabulated. The study 
utilized a multi-level mixed-effects logistic regression analysis to identify 
significant predictors of ESR and CRP measurement at clinical encounters, 
patient, physician and clinic levels. The fit of the final model was examined using 
receiver operator characteristic (ROC) curve analysis. Unmeasured variation 
attributable to each cluster of data was quantified using intra-class coefficients 
and median odds ratios.    
 
Results: There were 92,062 clinical encounters (level 1), nested within 17,450 
patients (level 2) who were patients of  272 physicians (level 3) from a total of 
100 clinics (level 4). Significant predictors included ordering other laboratory tests 
(OR:2.61; 95% CI: 2.3,2.9), number of previous DMARD prescriptions (OR:0.96; 
95% CI: 0.94,0.98) , female gender (OR: 1.09; 95% CI: 1.00,1.18), disease 
duration (OR: 0.99; 95% CI:0.992,0.999) , no insurance (OR: 0.37; 95% CI: 
0.27,0.49), physician propensity to order either ESR or CRP (OR: 1.46; 95% 
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CI:1.34,1.59) and private clinics (OR: 0.40; 95% CI: 0.20,0.81). Quantitative 
disease activity measures were not significantly predictive of ESR or CRP 
measurement. ROC curve analysis indicated a substantial fit of the final model 
(AUC=0.871). Variation in the measurement of an ESR and CRP was attributable 
to patient and clinic characteristics and not the individual physician.  
 
Conclusion: ESR and CRP measurement was not associated with disease 
activity levels. The use of ESR and CRP tests in the clinical management of RA 
should be reevaluated.  
 
Key words: ESR, CRP, Acute phase reactant, DAS28, disease activity  
 
measures  
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3.2 Introduction 
 
 
 
Evaluative laboratory tests, such as acute phase reactants (APRs) – 
erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), have long 
been used in the clinical management of RA to assess disease activity and guide 
treatment (1-4).  They are part of the American College of Rheumatology (ACR) 
core data set (5) for measuring disease activity and are used in the calculation of 
three composite disease activity measures: the disease activity score (6, 7)(DAS) 
and its modified version with 28 joint count (DAS28) (8) and the simplified 
disease activity index (SDAI) (9). They are also part of criteria to assess 
response to treatment (10-12).  
With the advent of new therapeutic biologic agents, assessment of 
disease activity to guide treatment decisions was recently recommended by the 
ACR (13). Variability in the use of laboratory tests by rheumatologist’s in the 
United States (U.S.), such as the ESR and CRP, to assess disease activity in 
clinic care has been reported in prior studies (14, 15). And, results of the two 
tests are often not available to the clinician at the time of the clinical encounter, 
thus, preventing the assessment of disease activity and the calculation of the 
DAS28 and SDAI and their associated response criteria (16).  
 Only two studies (14, 15) were found that have examined the level of 
variation between rheumatologists in the measurement of ESR and CRP or the 
factors associated with their measurement.  Henke et al (14) found, in a sample 
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of 66 U.S. rheumatologists’, wide variation in the use of ESR to monitor patients 
with RA. Forty-three per cent never ordered an ESR test while 3% were found to 
order an ESR test at every clinical encounter. In contrast, Donald et al (15) in a 
survey of 575 US rheumatologists found that 43% reported ESR and/or CRP 
testing at every visit or almost every visit. Henke et al (14) found that differences 
in the individual physician practice styles were more important in the 
measurement of ESR then patient characteristics or practice incentives. In 
contrast, Donald et al (15) found that factors most important to testing practices 
included the clinical experience with the patient, evidence from the literature and 
the rheumatologist’s training. Clinician financial considerations were found to be 
of minimal importance when ordering laboratory tests.  This variation in the 
measurement of ESR or CRP may also be the result of the rheumatologists’ 
uncertainty surrounding the understanding of the value of using the tests (14).  
The relative value of the two tests is uncertain due to sparse and inconclusive 
literature. Some studies (17, 18) have found ESR to be the better test while other 
studies (19, 20) have found CRP superior. Wolfe et al (3) reported that both, ESR 
and CRP perform similarly in the clinic although CRP is the better test to 
measure acute phase. But a recent study (21) reported that neither ESR nor 
CRP is the better measure in the clinical setting and found no correlation 
between ESR or CRP and disease activity measures.  
To improve the clinical management of RA and facilitate consistent 
monitoring of disease activity in the clinic, an understanding of the measurement 
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practices of ESR and CRP in a clinical setting would be useful. Therefore, the 
goals of the study were (1) to measure the frequency of the measurement of 
ESR and CRP using data from a large, representative sample of patients in 
clinical care, the Consortium of Rheumatology Researchers of North America 
(CORRONA) registry (22); (2) to identify predictors of the measurement of ESR 
and CRP at a clinical encounter; and (3) to quantify the variability among 
rheumatologists when measuring the ESR and CRP. The study utilized a multi-
level modeling strategy to identify individual-level and population-level factors of 
the data instead of aggregating them only to the individual level. While most 
related work has focused on the individual patient level, this study focused on 
factors associated with clinical encounters, patients, physicians and their practice 
sites that may affect measurement practices of ESR or CRP in the clinic. 
  
 
3.3 Methods 
 
 
Design and study population 
In this longitudinal, population-based study to assess the measurement of 
ESR and CRP among rheumatologists, all clinical encounters of patients with 
RA, during the study period between October 1, 2001 and November 1, 2008, 
were included in the study sample (n=92,062). The sample had a four-level 
hierarchical data structure: clinical encounters (level 1) nested within patients 
(level 2), treated by an individual physician (level 3) who practiced from a clinic 
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(level 4). The study utilized a multi-level mixed-effects logistic regression analysis 
to account for the correlation between the observations (encounters), and 
clustering of the data at the patient, physician and clinic levels. The units of 
investigation in the study were the clinical encounter and each cluster. The study 
was approved by the local institutional review board.  
 
Data source  
Data for the study was obtained from the Consortium of Rheumatology 
Researchers of North America registry (CORRONA) (22). CORRONA is an 
independent registry of patients with RA, osteoarthritis (OA), psoriatic arthritis 
(PsA) and osteoporosis from multiple sites across the United States.  Since 2001 
the registry has enrolled 113 clinics, 272 rheumatologists and over 17,000 
patients with RA.  Data are collected prospectively from both patients and their 
treating rheumatologists using survey questionnaires. Information collected from 
the patient includes: demographics, functional status, assessment of pain, family 
history, medical co morbidities and the presence of morning stiffness and fatigue. 
Data collected by the physician includes: disease activity measures as measured 
using the ACR core criteria, data on laboratory measures including ESR, CRP, 
and rheumatoid factor (RF),  radiographic evidence of erosion and joint space 
narrowing, medication usage including disease modifying anti-rheumatic drugs 
(DMARDs), anti-inflammatory drugs (NSAIDs), biologics, and corticosteroids, 
treatment patterns, and adverse events . A separate questionnaire administered 
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to the physician upon enrollment into the registry collected information on 
physician demographics and practice characteristics.  Follow-up examinations 
occur at three month intervals and are completed during routine clinical 
encounters.   
 
Outcome measures   
 
To examine the measurement of ESR and CRP, three outcomes of 
interest were evaluated. The first outcome, “APR measurement”, was a 
composite of either ESR or CRP measurement. It was operationalized as a 
dichotomous variable coded ‘1’ if measurement occurred and ‘0’ if there was no 
measurement. The measurement of the individual components of this outcome 
variable, the ESR and CRP were also examined in separate analyses.  Both 
outcomes were operationalized as dichotomous and coded ‘1’ if ESR or CRP 
were measured and coded as ‘0’ if no measurement occurred. If ESR or CRP or 
both were measured at a clinical encounter, the values were collected at the time 
of the clinical encounter and the physician recorded the values of these lab tests 
on a physician questionnaire.  
 
Predictors   
Potential predictors of the outcomes were abstracted from the 4 levels of 
the data and included (a) clinical encounter, (b) patient, (c) physician and (d) 
clinic. Variables corresponding to each category were defined and measured at 
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their respective level. Descriptions of these variables, their source and 
classifications are presented in Table 3.1.  
 
Clinic-encounter factors:  Since APR’s have been used to monitor 
inflammatory activity, disease activity may be predictive of their measurement. 
Therefore, the following physician-reported disease activity measures were 
assessed as predictors: presence of erosive disease and joint space narrowing, 
rheumatoid factor, tender joint with 28 count (TJC), swollen joint with 28 count 
(SJC), patient global assessment (PGA), physician global assessment (PhGA), 
and a composite measure, the Clinical Disease Activity Index (CDAI) (23). The 
DAS, DAS28 and SDAI were not included in the models because they contain an 
APR (ESR or CRP), but descriptive statistics for the measures were tabulated. 
Three patient-reported measures of disease activity were assessed for their 
influence on the measurement of an APR. These measures included the 
modified Health Assessment Questionnaire (mHAQ) (24, 25) a measure of 
functional status, level of pain (visual analog scale 0-100) and morning stiffness. 
Since an APR is often measured in conjunction with the ordering of other 
laboratory tests, a variable, “other laboratory tests” was derived to identify 
encounters where other lab tests had been ordered. The dichotomous indicator 
was coded as ‘0’ if no other tests were measured and ‘1’ if other tests were 
measured at a visit. Other laboratory tests in this variable included: cyclic 
citrullinated peptide, platelets, hematocrit, aspartate aminotransferease, alanine 
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aminotransferease, white blood cells, creatinine, albumin, PPD. Previous history 
of measurement of an APR may influence a measurement at a clinical encounter. 
Thus, a variable, “history of APR measurement”, was derived to indicate history 
of previous APR testing. It was derived by summing the number of previous 
encounters per patient where an ESR or CRP had been measured. Increased 
inflammation may result in therapeutic changes. Thus, the influence of current or 
past use of therapies to treat RA as predictors of the measurement of an ESR or 
CRP was examined. These included: the number of previous disease modifying 
anti-rheumatic drugs (DMARDs), current use of prednisone, and analgesics. The 
influence of treatment with gastrointestinal medications and antidepressants on 
the measurement of an APR was also examined.  Calendar year of examination 
was included as a potential factor because treatment recommendations for RA 
may have changed depending on the year.  
 
Patient-level factors: Patient characteristics examined in the analysis included: 
age, gender, duration of RA, marital status, education level, body mass index 
(BMI), smoking status, and insurance status. To examine the influence of 
medical comorbidities on the measurement of an APR, a variable, “comorbidity” 
was derived and included coronary artery disease (CVD), myocardial infarction 
(MI), congestive heart failure (CHF), stroke, diabetes, and cancer. It was 
operationalized as dichotomous with ‘0’ indicating no comorbidity and ‘1’ 
indicating the presence of a comorbidity from the above list. Anemia and 
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infections have been found to raise the level of ESR (26) and thus the presence 
of these conditions was assessed as predictors.         
 
Physician-level factors: Factors at the physician-level that were included in the 
analysis were physician gender, age, years in practice, the proportion of 
managed care in the physician’s practice, and the influence of formulary 
restrictions. If the physician has a high proportion of managed care in their 
practice, then frequency of laboratory testing may be restricted.  The physician’s 
past propensity to order an APR and its association with ordering an APR was 
examined. A variable, “physician propensity to order APR tests”, was derived by 
calculating the mean number of tests previously ordered by an individual 
physician across their patient visits.  
 
Clinic-level factors: Two clinic characteristic variables were assessed in the 
analysis and included the type of clinic (academic or private) and its geographical 
location. 
 
 Statistical analysis 
Descriptive statistics of the predictors of measurement of an APR from 
each data level were calculated according to their APR measurement status and 
their mean values and standard deviations are presented.  The frequency of a 
rheumatologist’s measurement of the three outcomes was tabulated. To improve 
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the robustness of the study results, the study sample was randomly and evenly 
divided into a training (n=46,091) and test (n=45,971) data set. The training 
dataset was used to develop the models and the test dataset was used to test 
the model fit. The model-building process consisted of 3 stages. First, univariate 
models were constructed using multi-level univariate mixed-effects logistic 
regression to examine the relationship between all potential predictors and the 
outcome. Second, variables that were significantly associated with an outcome at 
the p<0.10 level were retained for inclusion in subsequent multi-level 
multivariable mixed-effects logistic regression models and all other variables 
were excluded.  Third, all remaining significant predictors were evaluated in a 
final multi-level multivariate mixed-effects logistic regression model and retained 
if p<0.05.  This final model incorporated the most predictive variables from each 
of the four data levels. Separate modeling was repeated for the measurement of 
an ESR and the measurement of a CPR. All analyses were performed using the 
STATA software 10.1 (27). 
 
Multi-level Models 
Five multi-level mixed-effects logistic regression models were constructed 
separately for each of the three outcomes. The models are mixed-effects 
because some of the coefficients are modeled as fixed and others are random. In 
these analyses, the fixed effects were clinical encounter, patient, physician and 
clinic characteristics and each cluster defined as patient, physician and clinic, 
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were the random effects. The first model was an empty model containing no 
predictors.  The second model (level 1), contained the encounter-level variables 
significant in univariate analysis. The third model (level 2), was extended to also 
include significant patient-level variables. The fourth model (level 3) was 
extended to include significant physician-level variables. The fifth model (level 4) 
was the combined model and extended to include significant clinic-level 
variables. Since the multi-level analysis involved 4 levels, a 4-stage system of 
equations was conceptualized. The probability of the outcomes for clinical 
encounters i of the patient j seeing the physician k from the clinic l was 
examined.  
 
Level 1 model:  
The level 1 model is specified to compare clinical encounters with the outcome 
which were from the same patients (Equation 1). For example, an APR 
measurement for an encounter i in a patient j is modeled as:  
 
                     Logit (APRij) = β0j  +  β1jXij     (1) 
 
where the dependent variable, APR measurement (APR), distinguished between 
those clinical encounters  that had an APR measured (1) and those that did not 
(0) and Xij  is the clinical encounter variable. The probability of an APR 
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measurement for each encounter is modeled as a function of factors at the 
encounter-level which were significant in bivariate analysis. 
 
Level 2 model:  
The level 2 model takes into account the differences between the patients and 
explains these differences in terms of patient characteristics at this level. In 
equation 2, the intercept from level 1 (β0j ), equation 2, was modeled as a 
function of significant patient-level predictors of the outcome. This modeling 
means that within-patient random intercepts (µ0j) of each patient vary 
systematically with the patient characteristics that were significant in bivariate 
analysis.     
                              β0j = β00 + β01 Xj + β02 Xj  + µ0j                 (2)   
 
Level 3 model:  
The level 3 model takes into account the differences between the physicians and 
explains these differences in terms of physician characteristics at this level. In 
equation 3, the intercept from level 2 (β00), equation 2, was modeled as a 
function of significant physician-level characteristics from the bivariate analysis. 
This modeling means that within-physician intercepts (µ0k ) of each physician vary 
systematically with physician characteristics.    
 
                       β00 =  β0k + β01 Xjk + β02 Xjk+  β03 Xjk  + µ0k                 (3)   
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Level 4 model:  
The level 4 model takes into account the differences between the clinics and 
explains these differences in terms of clinic characteristics at this level. In 
equation 4, the intercept from level 3 (β0k), equation 3, was modeled as a 
function of significant predictors at the clinic level.  This modeling means that 
within-clinic random intercepts of each clinic (µ0l ) vary systematically with these 
significant predictors.      
                               Β0k =  β0j +   β01 Xl   +   β02 Xl +   µ0l                 (4)   
 
Combined Model:  
The combined model is described in equation 5 by substituting equations 4 into 3 
then 3 into 2 and then 2 into 1.   
 
Logit(APR jkl)  =  β00 +  β1jXij  +  β01 Xj  +  β02 Xj  +   β03 Xjk  +  β04 Xjk +  
 β05 Xjk  +  β06 Xl  +  β07 Xl   + µ0j   +    µ0k    +  µ0l            (5) 
 
 
Fixed effects (measures of association) 
The associations of APR measurement and the statistically significant 
factors at the clinical encounter-, patient-, physician- and clinic-levels are 
presented as odds ratios (OR) with their 95% confidence interval (CI).  
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Random effects (measures of variation)  
Measures of random effects included the random intercept variance, intra-
cluster correlation (ICC), and median odds ratio (MOR). The ICC is a measure of 
dependence or correlation among the dichotomous responses for the same 
subject or between subject heterogeneity. It was calculated according to the 
formula used by Rabe-Hebeth et al (28). An alternative measure of 
heterogeneity, the median odds ratio (MOR) (29, 30) was also used to quantify 
the unexplained cluster heterogeneity.  
 
 
Model fit  
 
Multi-collinearity or the correlation among independent variables was 
examined using the variable inflation factor (VIF) (31). Variables found to have a 
VIF >2 were excluded from further modeling.  To test the assumption of linearity 
of the independent continuous variables with an outcome, the Box-Tidwell 
transformation (32) was performed. In this test, interaction terms which are the 
cross-product of each independent variable time its natural logarithm are 
calculated and then added to the model. If these transformations are significant 
then there is nonlinearity in the logit. Linearity was also tested graphically by 
plotting the log odds for each of the probabilities of the outcome compared to the 
independent variable. Model fit to the observed data was determined using 
receiver operating characteristic (ROC) curve analysis (33) and plotting the area 
under the curve (AUC) (34). 
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3.4 Results 
 
Sample characteristics 
As shown in Table 3.2, there were 92,062 clinical encounters (level 1), 
nested within 17,450 patients (level 2) who were patients of  272 physicians 
(level 3) from a total of 100 clinics (level 4). Among the 92,062 encounters, an 
APR measurement occurred in 47,164 (51%) visits. Of theses visits, 39,400 
(43%) were measurements of ESR, and 28,327 (31%) were measurements of 
CRP. Both the mean ESR (23.86 mm/h) and the mean CRP (2.63mg/dL ) values 
were normal (abnormal ESR>25mm/h and abnormal CRP≥0.5mg/dL) (35).      
Clinic encounters where an APR was measured had a mean (SD) CDAI 
and DAS28 scores of 11.66 (11.5) and 3.4 (1.5), respectively, indicating low to 
moderate disease activity.  The proportion of other disease activity measures 
was similar across both types of visits. Two variables, “other laboratory tests” and 
“history of APR measurement” differed between the encounters. In encounters 
where an APR had been measured, the average number of other laboratory tests 
ordered was 50% higher compared to encounters with no APR measurement. In 
encounters with an APR measurement, the number of previous APRs was 
almost 4 times higher then in encounters with no APR measurement.    
Patients in the study sample were mostly female (75%) aged 60.3 years 
on average and had an average disease duration of 11.7 years. Their average 
(SD) BMI was 29.15 (9.3) and 15% were smokers. Most had private insurance or 
                                                                            
91
 
Medicare and approximately 3% had no insurance. The proportion of patient 
characteristics were similar in encounters where an APR was measured 
compared to those where no measurement occurred.  
Most physicians in the study sample where male (85%), were on average 
55.89 years old had had practiced on average 24.46 years.  70% had at least 
25% or more managed care in their practices and more had frequent formulary 
restrictions (55% to 44%).  The proportion of physician characteristics was similar 
across encounters with the exception of physician practice years. In encounters 
with an APR measurement, physicians had been in practice slightly less years 
compared to visits with no APR measurement. Clinics were primarily private and 
located mostly in the Northeast and Midwest.   
 
Frequency of APR measurement  
Large differences were found among the rheumatologists in their 
measurement of the three outcome variables of interest (Table 3.3). On average 
a rheumatologist measured one APR test (i.e.-ESR or CRP or both) at a clinical 
encounter. Measurement of ESR tests was done in 51% of the visits of the 
average rheumatologist, but one quarter of the rheumatologists ordered this test 
in 38% or less of their encounters and another one quarter in 83% or more. 
Testing for CRP was performed in 31% of the clinical encounters.     
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Univariate analysis  
Descriptive results from univariate analysis for variables significantly 
associated with a rheumatologists’ decision to measure an ARP at a p≤0.10 level 
are presented in Table 3.4. Variables are grouped in the four hierarchical levels 
of the data listed earlier. More then half (n=21) of the 40 factors assessed for 
associations with the measurement of an APR were statistically significant when 
compared in univariate analysis. Disease activity measures such as the CDAI 
were not found to be significant predictors of the measurement of an APR and 
were not retained for further analysis. Univariate results for the second and third 
outcomes of interest, measurement of an ESR and measurement of a CRP were 
similar to the results for outcome one and are not presented.   
 
Fixed effects (measures of association) 
The multivariate analysis identified seven variables that were most 
strongly associated with APR measurement at p≤0.05 level (Table 3.5). Odds 
ratios indicate the likelihood that an event will occur relative to the likelihood that 
it will not. Having other laboratory tests ordered at the visit increased the odds of 
having an APR measured by more than 2- fold. Encounters where there was a 
past history of DMARD use were 4% less likely to have a measurement of an 
APR. Female patients had a 10% increase in the odds of having an APR 
measurement and patients without any insurance coverage had a 60% less likely 
chance of an APR measurement. Disease duration was inversely related to 
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having an APR measurement. Increased propensities by a rheumatologist to 
order an APR increased the likelihood of an APR measurement. A clinic that was 
private had significantly lower odds of measurement of an APR test compared to 
an academic clinic.  The variable “history of APR testing” was dropped from the 
model because of multi-collinearity. Using the test dataset (n=45,971), the fit of 
the final model was assessed by ROC curve analysis. The area under the curve 
was 0.8137 and indicated that the model had substantial ability to discriminate 
between encounters with an APR measurement compared to those without 
(Figure 3.1).  
 Multivariate results for the second and third outcome, measurement of an 
ESR and measurement of CRP, respectively, were very similar to the results 
listed above and thus are not reported. The only exception was the type of clinic 
was not a significant predictor in the measurement of ESR.  
 
Random effects (measures of variation)  
The amount of residual or unexplained variation attributable to variability 
between patients, physicians and clinics for outcome 1, measurement of an APR, 
is presented in Table 3.6. Unmeasured differences between clinics and between 
patients represent the largest amount of variability not explained by the model. In 
model 1 (empty model), there was variation in the log odds of the measurement 
of an APR across the clinics (τ =2.03), across physicians (τ =0.89) and across 
patients (τ =0.67). According to the intra-clinic and intra-physician and intra-
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patient correlation coefficients, 29.5%, 12.9% and 9.7% of the variance in the 
measurement of an APR could be attributed to clinic, physician and patient 
factors, respectively.  After controlling for visit-, patient-, physician- and clinic-
level factors in the full model (Table 3.6, Model 5), the variance in the 
measurement of an APR was decreased for intra-physician to 5.1% but 
increased for intra-clinic and intra-patient to 29.6%, and 14.8%, respectively.     
Results form the MOR also confirmed evidence of patient and clinic 
characteristics shaping physician attitudes towards measuring an APR.  The high 
MOR (3.09) in the final model (Table 3.6, Model 5) between encounters in a clinic 
suggests that the clinic heterogeneity in the measurement of an APR is 
substantial. The MOR between encounters within physicians with a higher 
compared to a lower propensity to measure an APR was 1.60. This low odds 
ratio suggests that the clustering effect is low at the physician level. Thus there 
was little evidence of variations between physicians when measuring an APR.   
  
3.5 Discussion 
 
Using data from a large observational cohort of patients’ representative of 
a clinical care setting, results of the study indicate less than half of the visits had 
a measurement of ESR and less than a third had a CRP measurement, a finding 
in contrast to results of a recent study where most rheumatologists reported 
measuring ESR and CRP at most of their clinical encounters (15). Several 
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significant predictors of the measurement of an APR were identified in 
multivariate analysis including the ordering of other laboratory tests at the clinical 
encounter, the number of previous DMARDs prescribed, several patient 
characteristics, the propensity of the physician to order APR tests and the type of 
clinic. The study also found a wide variation among rheumatologists when 
ordering the measurement of an ESR or CRP. Most of the clustering effects were 
due to clinic and patients characteristics rather than individual physicians. Thus 
efforts to further explore the variability in the measurement of an APR should be 
targeted towards the clinics and also at individual patients and not at individual 
physicians.  
The discrepancy between the frequency of measurement of an ESR and 
CRP in our study compared to a prior study which reported over 85% of 
physicians measuring ESR and CRP at every clinical encounter may be due to 
the sampling inconsistencies. In the prior study, data was collected using a mail 
survey with only 29% of rheumatologists responding. Thus, the finding that most 
rheumatologists are measuring ESR or CRP may be overinflated especially if the 
rheumatologist who did not return the questionnaires did not routinely measure 
ESR or CRP. Since our study utilized data from a large observational registry of 
patients with RA from across the United States that are representative of clinical 
care setting, our finding of limited ESR and CRP testing are most likely accurate.  
 The ordering of other laboratory tests at a clinical encounter significantly 
increased the likelihood that an APR would be ordered. This finding suggests 
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that rheumatologists may be primarily ordering the measurement of an APR 
because they are part of a standard battery of routinely ordered tests and not 
because of a specific reason. Further research needs to be conducted to verify 
this finding.      
The number of previous DMARDs prescribed was inversely related to the 
measurement of an APR, and thus an increased number of past DMARD 
prescriptions would mean a less likelihood that an APR would be ordered.  
Frequent switching of DMARDs is recommended by the ACR treatment 
recommendations if maximum treatment response is not achieved (13). This 
finding seems to indicate physicians may not be using ESR or CRP 
measurements to guide therapy decisions, a finding supported form a recent 
study (15).  
Patient characteristics predictive of an APR measurement were female 
gender, having no insurance coverage and having greater disease duration. 
Female patients were found to have an almost 10% increased probability of 
having an APR measurement. This could be due to several factors such as 
patient demand for more testing or because values of ESR are known to be 
higher in women than men.  This result would need to be further evaluated to 
determine why female gender increases the probability of having an APR done. 
Predictably, having no insurance coverage was directly related to not receiving 
an APR measurement with 60% less likely an APR measurement would be 
ordered. Thus this finding indicates insurance status does play a role in the 
                                                                            
97
 
measurement of an APR.  And patients with a longer duration of disease had 
lower odds of having a measurement of an APR. This is reflective of previous 
research that reports older patients receive less therapy changes (36). 
A physicians’ past propensity of ordering laboratory tests such as the ESR 
or CRP influenced the measurement of an APR with an almost 50% increase in 
the probability of  a measurement if the physician had a higher past propensity. 
Thus physicians who have a proclivity to order APR tests in the past will be more 
likely to order them in the future. This finding might be the result of an individual 
physicians’ past training or practice style. One clinic characteristic was found to 
be significantly predictive of an APR measurement. This study found that an APR 
would be more likely to be measured at an academic clinic rather than a private 
clinic. This result is consistent with a similar result found in another study (15). 
This finding could be due to academic sites having superior testing capability with 
laboratory facilities compared to private clinics that would most likely not.  
ESR and CRP have long been thought to be used to monitor disease 
activity and response in patients with RA but the results of this study found the 
measurement of an APR was not associated with disease activity measures. This 
supports the results reported by Donald et al that physicians are measuring ESR 
but not using it to guide therapy. Also this confirms results found recently by 
Keenan et al (21) that ESR or CRP were not correlated with any disease activity 
measures.  Thus, based on the results of this study, rheumatologists are not 
measuring an APR to monitor disease activity or treatment decisions.  
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The study has several strengths. First, it is a large, population-based 
nationally-representative study with data from numerous private and academic 
clinics from four geographic regions across the United States. Thus the results 
can be generalized to most areas of the country.  Second, the study design was 
longitudinal and the effects of correlation and clustering were accommodated by 
the utilization of a multi-level modeling strategy.  A multilevel approach analyzes 
the social, cultural and economic context in which individual patient experience 
health outcomes. Beyond their physicians, individual patients will be influence by 
the clinics that their physician practices from and how they perceive 
measurement of an APR. Therefore, using a multilevel approach, we were able 
to study the associations of different levels that correspond to health care and 
provide more robust evidence about individual, physician and clinic factors that 
influence the measurement of an APR. Understanding the relative contribution of 
these factors from these levels is important towards understanding how 
physicians determine whether to measure an APR. Third, the study utilized 
training and test datasets to test the fitted model and thus increased the 
robustness of the results. Lastly, the number of included clinics, physicians and 
patients in the study and geographic diversities strengthen the findings from the 
study. A potential limitation to this study is that there was no information about 
testing equipment in the clinics which might explain why the APR measurement 
was low in private clinics.   
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Multilevel analysis was used to control for clustered data but other 
statistical procedures also account for clustering such as GEE modeling or 
alternating logistic regression (ALR).  A multi-level modeling approach was 
utilized because the study was interested in the average change at the individual 
level and to allow the effects of factors at different levels to be used. Conversely, 
ALR and GEE modeling estimate a population-averaged approach which was not 
related to the study’s objective.   
 In conclusion, the results of this study indicate that measurement of an 
APR in the clinic is influenced by physician practice decisions. If other laboratory 
testing are ordered and if the physician has a propensity to order an APR, then 
the probability of an APR measurement was increased. Several patient 
characteristics were associated with APR measurement including gender, and 
insurance status. The study did find that most of the unexplained variability in the 
measurement of an APR was due to differences at the clinic and patient levels 
and not the individual physician. Lower variation among physicians may indicate 
that most physicians are unclear as to when to measure an APR, suggested by 
Wolfe et al (3). Since many other tests are available to physicians, measurement 
of ESR and CRP may only be done in conjunction with other lab tests, a finding 
supported by our results. Based on these findings, future public health 
interventions to standardize APR testing in an effort to contain costs could be 
focused on clinic and patient levels instead of the individual physician. 
Surprisingly, the study found that disease activity levels were not associated with 
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the decision to measure an APR. This finding may suggest that measurement of 
an APR is not ordered to monitor disease level or to guide treatment decisions. 
Rethinking the role of ESR and CRP in the clinical management of RA may be 
warranted.    
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Table 3.1 Variables used in the models and associated data sources and 
definitions 
Factor Source Classification 
Level 1: Clinical encounter level  
Rheumatoid factor Physician  yes vs. no (reference) 
Erosive disease Physician  yes vs. no (reference) 
CDAI administrative  continuous variable 
Tender joint count Physician  0-28 
Swollen joint count Physician  0-28 
PGA  Patient 0-100 
PhGA  Physician 0-100 
Pain Score patient; visual analog scale  0-100 
Functional Status patient; measured by mHAQ 0-3  
Morning Stiffness patient  continuous variable 
Calendar year of examination Physician  continuous variable 
Morning stiffness patient  continuous variable 
Other laboratory tests± Physician  yes vs. no (reference) 
No. of previous APR tests Physician continuous variable 
No. of previous DMARDs Physician continuous variable 
DMARDs Physician yes vs. no (reference) 
Prednisone  Physician yes vs. no (reference) 
Gastrointestinal¶ Physician yes vs. no (reference) 
Analgesics* Physician yes vs. no (reference) 
Antidepressants§ Physician yes vs. no (reference) 
Level 2: Patient level 
Patient gender patient  male (reference) vs. female  
Race: white patient  yes vs. no (reference) 
Patient age , year patient  continuous variable 
Duration of RA physician  continuous variable 
Married patient  yes vs. no (reference) 
Education level patient  completed college vs. not 
completed (reference) 
BMI patient  continuous variable 
Smoker patient  yes vs. no (reference) 
Insurance status patient   
            Private patient  yes vs. no (reference) 
            None patient  yes vs. no (reference) 
            Medicare patient  yes vs. no (reference) 
            Medicaid patient  yes vs. no (reference) 
Comorbidity€ physician  yes vs. no (reference) 
Infection Physician  yes vs. no (reference) 
Anemia patient   
Level 3: Physician level 
Physician gender Physician  male vs. female (reference) 
Physician age, years Physician  continuous variable   
Physician years in practice Physician  continuous variable   
Managed care Physician  <25% (reference), 25-50%, 
>50%; percent in practice 
Formulary restrictions  Physician  frequently (reference) vs. 
infrequently; influence on 
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±other lab tests include: cyclic citrullinated peptide, platelets, hematocrit, aspartate 
aminotransferease, alanine aminotransferease, white blood cells, creatinine, albumin, PPD 
BMI-body mass index; APR-acute phase reactants (APR refers to ESR or CRP in this study) 
mHAQ- modified Health Assessment Questionnaire; CDAI- Clinical Disease Activity Index; 
DMARDs- disease modifying anti-rheumatic drugs; PGA-physician global assessment; PhGA-
physician global assessment.     
*Analgesics include:   
¶ Gastrointestinal medications include:  
§Antidepressants include:  
€comobidities include: hypertension, cancer, diabetes mellitus, congestive heart failure, coronary 
artery disease, myocardial infraction, stroke 
£ northeast –Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont, New 
York, New Jersey, Pennsylvania; Midwest-Indiana, Illinois, Michigan, Ohio, Wisconsin, Iowa, 
Kansas, Minnesota, Missouri, Nebraska, North Dakota, South Dakota; south- Dellaware, District 
of Columbia, Florida, Georgia, Maryland, North Carolina, South Carolina, Virginia, West Virginia, 
Alabama, Kentucky, Mississippi, Tennessee, Arkansas, Louisiana, Oklahoma, Texas; west-
Arizona, Colorado, Idaho, New Mexico, Montana, Utah, Nevada, Wyoming, Alaska, California, 
Hawaii, Oregon, Washington.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
prescribing   
Level 4: Clinic level  
Clinic type Physician  academic (reference) vs. 
private  
Geographic location£ Physician  northeast (reference), 
midwest, south, west  
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Table 3.2 Descriptive characteristics of clinical encounters by APR* 
measurement status (n=92,062) 
Characteristics  N Total Sample (n=92,062) 
     APR 
Measurement 
(n=47,164)  
No APR 
Measurement 
(n=44,898) 
Level 1: Clinical encounter  (n=92,062)
ESR, mean (SD) 39400 23.86(21.0) 23.86 (21.0) ---- 
CRP, Mean (SD) 28327 2.63(7.6) 2.63 (7.6) ---- 
Rheumatoid factor, % (SD) 19703 0.71(0.46) 0.71 (0.45) 0.69 (0.46) 
Erosive disease, % (SD) 18299 0.50 (0.49)  0.49 (0.50) 0.49 (0.49) 
Joint space narrowing, % (SD) 18489  0.64 (0.48) 0.65 (0.47) 0.63 (0.48) 
CDAI, mean (SD) 85276 11.9 (11.71) 11.66 (11.54) 12.15 (11.81) 
DAS28, mean (SD) 36829 3.38 (1.49) 3.38 (1.49) ---- 
SDAI, mean (SD) 26917 14.1 (14.71) 14.09 (14.71) ---- 
Tender joint count, mean (SD) 91234 3.11 (5.2) 3.09 (5.1) 3.12(5.3) 
Swollen joint count, mean, (SD) 91248 3.97 (5.6) 4.15(5.9) 3.81 (5.3) 
PGA, mean (SD)  86139 28.48 (24.9) 28.17 (24.9) 28.80 (24.9) 
PhGA, mean (SD)  91767  19.51 (18.5) 19.17 (18.13) 19.87 (18.78) 
Pain Score, mean (SD) 87430 30.81(25.4) 30.26 (25.26) 31.39 (25.53) 
mHAQ, mean (SD)  88736 0.37 (0.46) 0.36 (0.46) 0.37 (0.46) 
Morning stiffness, % (SD) 88350 0.94 (2.12) 0.93 (2.16) 0.96 (2.07) 
Other laboratory tests±, % (SD) 92062 0.09 (0.28) 0.12 (0.33) 0.06 (0.23) 
No. of previous APR tests, mean (SD) 92062 2.6 (2.93) 3.79 (3.12)  1.28 (2.84) 
DMARD, % (SD) 92062 0.14 (0.34) 0.14 (0.35) 0.13 (0.34) 
No. of previous DMARDs, mean (SD) 92062 1.31 (1.56) 1.27 (1.55) 1.34 (1.57) 
Prednisone, % (SD) 91415 0.32 (0.47) 0.31 (0.46) 0.33 (0.49) 
Gastrointestinal, % (SD) 92062 0.35 (0.48) 0.35 (0.48) 0.36 (0.48) 
Analgesics, % (SD) 92062 0.60 (0.49) 0.60 (0.49) 0.60 (0.48) 
Antidepressants, % (SD) 92062 0.26 (0.49) 0.25 (0.43) 0.27 (0.46) 
     
Level 2: Patient  (n=17,450) 
Age , mean (SD), y 91694 60.3 (13.2) 60.41 (13.3) 60.1 (13.8) 
Sex , % female (SD) 92019 0.75 (0.43) 0.76 (0.43) 0.75 (0.43) 
Ethnic origin, % Caucasian (SD) 91084 0.86 (0.39) 0.85 (0.34) 0.87 (0.34) 
Disease duration,  mean(SD), y  91604 11.7 (9.90) 11.7 (10.11) 11.7 (9.8) 
BMI, mean (SD) 90065 29.15 (9.3) 29.07 (9.1) 29.23 (9.8) 
Smoker, % (SD) 89055 0.14 (0.35) 0.14 (0.35) 0.15 (0.35) 
Insurance status, % (SD)     
      Private 80377 0.73 (0.44) 0.73 (0.44) 0.73 (0.44) 
      No insurance  80377 0.01 (0.11) 0.01 (0.10) 0.02(0.13) 
      Medicare 80377 0.42 (0.49) 0.43 (0.49) 0.41 (0.49) 
      Medicaid 80377 0.06 (0.23) 0.06 (0.24) 0.06 (0.23) 
Comorbidities, % (SD) 92062   0.076 (0.27) 0.077 (0.27) 0.076 (0.27) 
Anemia, % (SD) 88767 0.25 (0.43) 0.25 (0.43) 0.25 (0.43) 
Infections, % (SD) 91909 0.17 (0.37) 0.18 (0.38) 0.15 (0.35) 
     
Level 3: Physician  (n=272) 
Age, mean (SD) 83898 55.9 (6.60) 55.6 (6.97) 56.2 (6.17) 
Sex, % male (SD) 86580  0.85 (0.36) 0.85 (0.36) 0.85 (0.35) 
Years in practice, mean (SD) 84222 25.47 (52.4) 24.13 (18.18) 26.86 (72.3) 
Percent of managed care in practice, 
% (SD) 
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        <25% 23646 0.26 (0.44) 0.29 (0.45) 0.22 (0.41) 
        25-50% 24045 0.26 (0.44) 0.24 (0.43) 0.28 (0.45) 
        >50% 36925 0.40 (0.45) 0.38 (0.49) 0.42 (0.49) 
Formulary restrictions, % (SD)      
        Frequently 47556 0.52 (0.49) 0.51 (0.49) 0.52 (0.49) 
        Infrequently 39820 0.41 (0.49) 0.41 (0.49) 0.41 (0.49) 
     
Level 4: Clinic (n=100) 
Type of clinic, % (SD)     
       Academic 10975 0.12 (0.32) 0.13 (0.31) 0.10 (0.30) 
       Private 73146 0.79 (0.40) 0.79 (0.42) 0.82 (0.38) 
Geographical region, % (SD)     
       Northeast 43357 0.47 (0.49) 0.47 (0.49) 0.47 (0.48) 
       Midwest 22592 0.25 (0.43) 0.28 (0.45) 0.21 (0.41) 
       South 13667 0.15 (0.35) 0.10 (0.30) 0.20 (0.39) 
       West   5683 0.06 (0.24) 0.06 (0.24) 0.06 (0.23) 
     
*APR-acute phase reactants (in this study refers to erythrocyte sedimentation rate and C-reactive 
protein) 
±other lab tests include: cyclic citrullinated peptide, platelets, hematocrit, aspartate 
aminotransferease, alanine aminotransferease, white blood cells, creatinine, albumin, PPD. 
ESR-erythrocyte sedimentation rate; CRP- C-reactive protein; CDAI- Clinical Disease Activity 
Index; DAS28- Disease Activity Score 28; SDAI=Simplified Disease Activity Index; BMI-body 
mass index; mHAQ- modified health assessment questionnaire; PGA-patient global assessment; 
PhGA-physician global assessment. 
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Table 3.3  Observed Variation: Propensity to use tests among rheumatologists in 
clinical encounters (n=92,062)                                                                              
                                                                                        Distribution  
Outcome  Mean SD Minimum First quartile Median 
Third 
quartile Maximum
 
No. APR tests 
done 
 
1.18 
 
0.72
 
0.00 
 
0.46 
 
1.08 
 
1.88 
 
2.00 
 
No. ESR done 
 
0.51 
 
0.41
 
0.00 
 
0.38 
 
0.58 
 
0.83 
 
1.00 
 
No. CRP done 
 
0.31 
 
0.27
 
0.00 
 
0.12 
 
0.35 
 
0.48 
 
1.00 
 
APR-acute phase reactant; ESR-erythrocyte sedimentation rate; CRP- C-reactive 
protein 
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Table 3.4 Univariate analysis of rheumatologist’s decision to measure an APR at 
a clinical encounter (training dataset: n= 46,091) 
±other lab tests include: cyclic citrullinated peptide, platelets, hematocrit, 
aspartate aminotransferease, alanine aminotransferease, white blood cells, 
creatinine, albumin, PPD. 
DMARDs –disease modifying anti-rheumatic drugs; APR- acute phase reactant 
 
Variable 
  
Odds Ratio (95% CI) P Value 
Level 1 : Clinical encounter 
Other laboratory tests± 2.59 (2.36-2.83) 0.00 
History of APR tests 1.46 (1.44-1.47) 0.00 
No of previous DMARDs 0.96 (0.94-0.98) 0.00 
Prednisone 0.94 (0.91-0.97) 0.00 
   
Level 2: Patient  
Patient age 1.00 (1.00-1.004) 0.01 
Female  1.05 (0.99-1.10) 0.00 
White 0.84 (0.78-0.89) 0.03 
Duration of RA 1.00 (0.99-1.004) 0.00 
Married 0.95 (0.91-0.99) 0.05 
College 1.05 (1.00-1.09) 0.06 
No insurance 0.87 (0.58-0.76) 0.00 
Medicaid 1.12 (1.04-1.19) 0.02 
Infections 1.03 (1.00-1.07) 0.03 
   
Level 3: Physician  
Physician age 0.97 (0.97-0.98) 0.00 
Male  0.83 (0.78-0.88) 0.00 
Practice years 0.99 (0.991-.0997) 0.00 
% managed care   
                         <25%  1.00   (Reference)  
                         25-50% 0.71 (0.67-0.75) 0.01 
                         >50% 0.72 (0.68-0.76) 0.02 
Infrequent formulary restriction 1.05 (1.00-1.10) 0.03 
Propensity to order lab tests 1.52(1.24-1.65)  0.00 
   
Level 4: Clinic   
Private  0.73 (0.68-0.77) 0.00 
Geographic region   
                       Northeast  1.00   (Reference)  
                       Midwest 1.34 (1.27-1.43) 0.02 
                       South 0.66 (0.62-0.71) 0.02 
                       West 1.09 (1.01-1.19) 0.01 
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Table 3.5 Multivariate model predicting rheumatologists’ decision to measure an 
APR at a clinical encounter (training dataset: n= 46,091) 
 
Variable  
 
Odds Ratio (95% CI) P Value  
 
Other laboratory tests± 
 
2.61  (2.33-2.93) 
 
0.00 
 
No. of Previous DMARDs 
 
0.96  (0.94-0.98) 
 
0.003 
 
Female 
 
1.09  (1.00-1.18) 
 
0.03 
 
Duration of disease 
 
0.99  (0.992-0.999) 
 
0.036 
 
No insurance coverage 
 
0.37  (0.27-0.49) 
 
0.00 
 
Propensity to measure APR tests 
 
1.46  (1.34-1.59) 
 
0.00 
 
Private clinic 
 
0.40  (0.20-0.81) 
 
0.01 
 
±other lab tests include: cyclic citrullinated peptide, platelets, hematocrit, 
aspartate aminotransferease, alanine aminotransferease, white blood cells, 
creatinine, albumin, PPD. 
DMARDs –disease modifying anti-rheumatic drugs; APR- acute phase reactant; 
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                  Figure 3.1 Receiver Operating Curve Analysis of full model to     
                  discriminate measurement of an APR (test dataset: n=45,971) 
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CHAPTER IV 
 
A Modified Rheumatoid Arthritis Disease Activity Score With 28 
Joint Count (mDAS28) For Epidemiological Research 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 The following work of the same name is currently under review by the Journal of 
Rheumatology.    
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4.1 Abstract 
 
Objective. To examine the measurement properties and validity of a modified 
version of the DAS28 (mDAS28), as an alternative measure of disease activity 
when laboratory results are unavailable. 
  
Methods.  In a cross-sectional development cohort (5,729 patients), statistically 
significant predictors of the logarithm of erythrocyte sedimentation rate (lnESR) 
were identified using linear regression analysis. After computation of the 
mDAS28, a cross-sectional validation cohort (5,578 patients) was used to 
evaluate criterion and construct validity of the mDAS28. The ability of the 
mDAS28 to discriminate between various disease states was also assessed. A 
second validation cohort (longitudinal-336 pairs of patient visits) was used to 
assess sensitivity to change.  
 
Results. Significant predictors of lnESR included tender joint count, swollen joint 
count, modified health assessment questionnaire (mHAQ), physician global 
assessment (PhGA) and patient pain score (VAS).  The mDAS28 had high 
criterion validity with strong Spearman-rank correlations with the DAS28, SDAI 
and CDAI (r= 0.87, r=0.91, r=0.96). Predictive validity was demonstrated by good 
correlation with the mHAQ (r=0.58). The mDAS28 showed substantial agreement 
with the DAS28, SDAI and CDAI when discriminating between disease states 
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(ĸ=0.70-0.77) and moderate to substantial agreement between response levels 
(ĸ=0.52-0.73). Both mDAS28 and DAS28 measures classified patients similarly 
in remission compared to the SDAI and CDAI. The mDAS28 was superior when 
detecting change (SRM =0.58) followed by the DAS28, CDAI and the SDAI. 
    
Conclusion. The mDAS28 is a valid and sensitive tool to assess disease activity 
and can be used as an alternative measure to the DAS28 when laboratory values 
are missing.  
 
Key words: DAS28, mDAS28, EULAR, disease activity measures, CDAI, SDAI  
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4.2 Introduction 
 
The Disease Activity Score with 28 joint count (DAS28) (1) is one of the 
most widely used and validated composite measures of disease activity in 
rheumatology. It is a modified version of the original Disease Activity Score 
(DAS), which was developed by van der Heijde et al (2, 3) in 1990. The DAS28 is 
calculated using the following parameters:  tender joint count (TJC), swollen joint 
count (SJC), visual analog scale of patient general health (PGA) and a laboratory 
value, the erythrocyte sedimentation rate (ESR). The DAS28 comprises the 
European League Against Rheumatism (EULAR) response criteria (4) used to 
measure response to treatment in clinical trials. Cut points to delineate disease 
activity levels and change in disease levels have been derived (4, 5).   
The DAS28 has been a reliable measure of treatment efficacy in clinical 
trials along with the American College of Rheumatology criteria (6) and its use 
has been recommended by the EULAR (7). In the clinical management of RA, 
the DAS28 is required by several regulatory bodies when determining patient 
eligibility for biologic treatments. In several research studies, the DAS28 has 
been a benchmark for validation of new composite indices (8-12).    
 However, the utility of the DAS28 has been limited, in epidemiological 
research using disease registry data, due to missing ESR laboratory values (13).  
In clinical trials, ESR values are available as mandated by study protocol thus 
allowing the computation of the DAS28. But in some practice settings, the ESR 
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laboratory test is not routinely ordered or not available during the patient visit, 
preventing the DAS28 from being calculated and omitting those patients from the 
analysis (14). 
 New simplified measures such as the Simplified Disease Activity Index 
(SDAI) (10) and the Clinical Disease Activity Index (CDAI) (8), offer some 
advantages over the DAS28 because of their simplified formulas. And the CDAI 
in particular does not require a lab value to be calculated (8). A recent literature 
review (15), reported that the SDAI and CDAI were found to be strongly 
correlated with the DAS28 in several studies. However, differences between the 
measurement performances of these simplified measures and the DAS28 were 
found. When assessing individual patients, classification of patients into 
remission differed between the measures.  
To facilitate the calculation of the DAS28 in epidemiological research 
using disease registry data, one approach would be to modify the DAS28 by 
replacing the natural logarithm of ESR (lnESR) with disease activity measures 
that are measurable at every clinical encounter. Thus, the DAS28 could be 
calculated when ESR values were unavailable. Therefore, the aim of this study 
was to develop a modified version of the DAS28 that does not contain the ESR: 
the modified DAS28 (mDAS28) and to assess its comparability with the DAS28 
and its validity according to the Outcomes Measures in Rheumatoid Arthritis 
Clinical Trials (OMERACT) recommendations (16, 17).  
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4.3 Patients and Methods 
 
 Subjects were selected from a large North American registry, the 
Consortium of Rheumatology Researchers of North America (CORRONA) (18). 
The methods of this registry have been described in detail elsewhere (19). 
Patients eligible for the study had all of the parameters necessary to calculate the 
DAS28.  Patients who did not have all of these components were excluded from 
further analysis. The demographic and disease activity measures of excluded 
and included patients were compared in a separate analysis to determine 
whether any bias was entered due to sample selection. 
 The study utilized 3 samples, cross-sectional “development” and 
“validation” datasets and a longitudinal “validation” dataset (Table 4.1).  
 The first two datasets were from a cohort of 11,307 RA patients. A cross-
section of this cohort was obtained by utilizing information from the patient’s most 
recent visit.  This cross-sectional cohort was randomly and evenly divided into 
“development” and “validation” datasets. The cross-sectional development 
dataset (n=5729) was used to build a prediction model to identify statistically 
significant predictors of the lnESR and the cross-sectional validation dataset 
(n=5578) was used to subsequently validate the mDAS28.     
 The third dataset, a longitudinal “validation” dataset was from a cohort of 
703 patients with RA who had two paired visits. The first visit contained an 
initiation of a disease modifying anti-rheumatic drug (DMARD) and the second 
                                                                            
115
 
visit occurred at least three months after the first. This longitudinal cohort was 
then divided randomly and evenly into “development “(n= 336 pairs) and 
“validation” datasets (n=367 pairs). The longitudinal validation dataset was used 
to evaluate the mDAS28 as a measure of response. 
 Disease activity parameters needed to compute the DAS28 were collected 
by a rheumatologist. Measures also collected included the modified Health 
Assessment Questionnaire (mHAQ) score (20), a measure of functional status, 
the patient visual analog score (VAS) pain score, physician global assessment of 
disease activity (EGA) and duration of morning stiffness. The DAS28 values were 
calculated according to its formula (2):  
 
DAS28= 0.56 * √(28TJC) + 0.28 * √(28SJC) + (0.70 * lnESR) + 0.014 * PGA 
 
SDAI and CDAI values were also calculated according to their formulas (8, 10) 
and used as comparators along with the DAS28 to validate the mDAS28. To 
validate the mDAS28 as a measure of response, response criteria, namely the 
EULAR response criteria, were used.  Response criteria for the SDAI and the 
CDAI, based on previously published absolute cut points (21) and change cut 
points (22) were also calculated and used as additional comparators.  
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Statistical analysis 
 To develop the mDAS28, statistically significant predictors of the lnESR 
were identified in the cross-sectional development cohort, using univariate linear 
regression analysis. Candidate predictors of lnESR included TJC, SJC, VAS, 
PhGA, PGA, mHAQ, and the duration of morning stiffness.  Candidate variables 
that were significant at an alpha level of 0.10 were included in a multivariate 
model. Forward and backward stepwise regression was used to identify the most 
significant independent variables using a P value of 0.10 as the removal criterion.   
Multi-collinearity between the significant independent variables, specified in the 
multivariable model, was determined using the variance inflation factor (VIF) (23). 
Variables found to be collinear (VIF>2) were dropped from the model.   
 The validity of the mDAS28 as a measure of disease activity and response 
was then evaluated in the cross-sectional and longitudinal validation datasets. 
Criterion validity or the extent that a measure correlates with a “gold standard” 
was examined by correlating mDAS28 scores with DAS28, SDAI and CDAI.  
Predictive validity, the ability of a measure to predict the future outcome of the 
disease was examined by correlating the mDAS28 scores with the mHAQ.  Both 
validities were assessed by Spearman-rank correlation coefficients (24).  The 
amount of agreement between the mDAS28 and the other disease activity 
indices to discriminate between different disease states of individual patients 
(remission, low, moderate, high) and between good, moderate or none levels of 
response based on the EULAR response criteria was examined using weighted 
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kappa statistics (25). The EULAR response criteria were calculated according to 
its algorithm in Figure 4.1. Since new cut points were not derived for the 
mDAS28, modified EULAR (mEULAR) response criteria were calculated 
according to the EULAR response criteria, using mDAS28 scores and DAS28 cut 
points.    
 The SDAI and CDAI response criteria were derived in the same manner 
as the EULAR response criteria, with the exception that the absolute cut points 
previously defined by Aletaha et al (21) and the change cut points defined by 
Ranganath et al (22) for both measures were used instead of DAS28 cut points.  
 The sensitivity to change or responsiveness of the mDAS28, the ability of 
a measure to detect important changes over time after a treatment has been 
initiated, was evaluated by calculating the effect size (ES) (26) and standardized 
response mean (SRM) (27). The effect size was calculated by taking the mean 
differences of the disease activity scores between the baseline and second study 
visits (mean change scores) and then divided by the standard deviation of the 
baseline scores. The SRM was calculated by taking the mean change scores 
and then dividing the result by the standard deviation of the change scores.  The 
values of the ES were small with a range of 0.2-0.5, moderate if 0.5-0.8 or large if 
>0.8 (26). The SRMs were interpreted similarly (28).  Statistical analysis was 
carried out using Stata version 10.0 (Stata Corporation, College Station, TX) 
(29). 
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4.4 Results 
 
 A total of 11,307 patients were eligible for the cross-sectional cohort and 
703 pairs of patients with an initiation of a DMARD and at least 3 months until the 
first follow up visit, were eligible for the longitudinal cohort. Demographics and 
clinical characteristics for the cross-sectional development and validation dataset 
were generally similar (Table 4.1). Both cross-sectional datasets exhibited mild to 
moderate disease levels but, in the longitudinal validation dataset, disease 
activity measures had higher values. This would be expected since the patients 
in the longitudinal dataset were initiators of DMARDs. A sensitivity analysis was 
performed between patients utilized in the study and the subset of patients who 
did not have sufficient parameters to calculate the DAS28 and their demographic 
and clinical characteristics were found to be comparable (data not shown).     
 
The modified DAS28 (mDAS28)  
 In the unadjusted univariate analysis, all seven candidate predictors (TJC, 
SJC, PGA, PhGA, VAS, mHAQ, and morning stiffness) were found to 
significantly predict lnESR. A forward and backward stepwise regression analysis 
resulted in the same multivariable model with the following significant predictors: 
TJC, SJC, mHAQ, PhGA, and VAS (Table 4.2).                 
 The PGA and duration of morning stiffness were significant in the 
unadjusted model but became insignificant when entered into the multivariable 
                                                                            
119
 
model. Upon examination of the functional associations between the lnESR and 
several of the candidate predictors, transformations of TJC and SJC were 
performed to better fit the assumption of linearity. The multivariable model was 
refit after transforming the TJC and SJC to their logarithmic forms. A separate 
model was fit using TJC and SJC in the forms of log of (TJC+1) and (SJC+1) due 
to values of 0. No differences in the amount of variance were explained by these 
models were found when compared to the original model.  In another series of 
models, TJC and SJC were both transformed to their square roots and refit in the 
multivariable model. Again no difference was found with the amount of variance 
explained by this model compared to the original model. It was decided to use 
the model containing the square roots of TJC and SJC since the transformed 
forms could be combined with the squared forms of TJC and SJC that were 
already present in the DAS28 formula. Every possible interaction between the 
variables was also explored but no significant interactions were found. The final 
model consisted of the five significant predictors of lnESR: TJC, SJC, mHAQ, 
VAS and PhGA.  The regression equation for the lnESR was as follows:  
 
lnESR= 2.42 –(0.0378 * √28TJC) + (0.0401 * √28SJC) + (0.35 * mHAQ) + 
(0.0014 *VAS) + (0.0077 * PhGA) 
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The possibility of multi-collinearity between the significant predictors was 
explored using the variance inflation factor (VIF) and no collinearity was 
indicated. All VIF values were less then 2.0 (range: 1.40-1.94).  
 Imputation of the fitted regression equation of the lnESR into the DAS28 
formula in place of the observed lnESR resulted in the following modified version 
of the DAS28: 
 
mDAS28= 0.56 * √(28TJC) + 0.28 * √(28SJC) + 0.70 [2.42 –(0.0378 *√28TJC) + 
(0.0401 * √28SJC) + (0.35 * mHAQ) + (0.0014 * VAS) 
+ (0.0077 * PhGA)] + 0.014 * PGA 
 
The formula was simplified to its final form by combining the squared TJC and 
SJC terms: 
 
        mDAS28= 0.534*√(28TJC) + 0.31*√(28SJC) + 0.245*mHAQ + 0.001*VAS + 
  
 
                                         0.005 * PhGA + 0.014 * PGA + 1.694 
 
 
Validation of the mDAS28 
Measure of disease activity 
 Distributional properties. The distributions of mDAS28 scores and the 
DAS28 scores differed, with the DAS28 being normally distributed and the 
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mDAS28 exhibiting right-skewness (Figure 4.2). The SDAI and CDAI values 
were also right-skewed as has been reported in several other studies (30, 31). 
 The means (SD) of the DAS28 and mDAS28 were 3.42 (1.54) and 3.41 
(1.38), respectively in the cross-sectional development dataset and were similar 
in the two validation datasets (Table 4.1). Upon further examination, it was found 
that both the mDAS28 and the DAS28 were almost identical in detecting 
remission and low disease activity. Using the DAS28: 894 (16%) of patients had 
scores of <= 3.2 and >2.6 (low disease) and 1,871 (34%) had scores of < =2.6 
(remission). When the mDAS28 was used: 915 (17%) of patients had scores of 
<=3.2 and >2.6 and 1,939 (35%) had scores of <=2.6 (Table 4.3).   
 When the CDAI was used to classify patients, a greater proportion of 
patients were classified into low disease and fewer into remission compared to 
the DAS28 and mDAS28. The proportion of patients classified into remission and 
low disease activity by the SDAI was similar to that of the CDAI (Table 4.3).     
 Criterion validity. On a group level, the mDAS28 was strongly correlated 
with the DAS28, SDAI and CDAI (r=0.87, 0.91 and 0.96, respectively). All 
correlations were significant at P<0.0000.   
 Predictive Validity. The mDAS28 was significantly correlated with the 
mHAQ, (r= 0.58, P< 0.0000). The DAS28, CDAI and SDAI were also found to be 
significantly correlated with the mHAQ but not as strongly (r= 0.51, r= 0.51, r= 
0.51, P< 0.0000).    
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 Ability to discriminate.  To determine the ability of the mDAS28 to classify 
individual patients by disease level, weighted kappa coefficients were used and 
indicated strong agreement between the mDAS28 with the DAS28 (ĸ= 0.70). 
Kappa values >0.60 indicate a substantial relationship (32). There was strong 
agreement between the mDAS28 and the CDAI (ĸ=0.77) and between the 
mDAS28 and the SDAI (ĸ =0.71).  Similar results were found between the DAS28 
and the CDAI and the DAS28 and the SDAI (ĸ =0.62, ĸ =0.63, respectively). 
 
Measure of response to treatment  
 Ability to discriminate.  Substantial agreement between the EULAR and 
the mEULAR when classifying individual patients was found (ĸ= 0.74). However, 
only a moderate agreement was found when the mEULAR was compared to the 
CDAI response criteria (ĸ= 0.52.) and the SDAI response criteria (ĸ= 0.52). 
Moderate agreements were also found when the EULAR response criteria was 
compared with the CDAI (ĸ= 0.46) and the SDAI response criteria (ĸ= 0.47).   
 Sensitivity to change. The mean change in scores of the mDAS28 and the 
DAS28 from the baseline initiation visit to the follow-up visit were similar (Table 
4).  The mDAS28 was the most sensitive measure to detect change over time 
compared to the DAS28, CDAI and SDAI. The mDAS28 had moderate ES and 
SRM values (0.50, 0.58) while the DAS28 and CDAI both had moderate SRM 
values (0.57, 0.52) but small ES values (0.47, 0.45). The SDAI was the weakest 
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measure to detect change with ES and SRM values of 0.37 and 0.45, 
respectively.  
 
4.5 Discussion 
 
 This study demonstrates that a modified version of the DAS28 calculated 
without the ESR, the mDAS28, performs as well as the DAS28 as both a 
measure of disease activity and response and could be used as an alternative 
measure to the DAS28 in epidemiological research when missing ESR values 
are unavailable.   
 Measures such as the DAS28 have been used successfully in clinical 
trials where the goal was to measure the efficacy of therapies by comparing 
groups of patients. In this study, the mDAS28 was strongly correlated with the 
DAS28, and also strongly correlated with the SDAI and CDAI on a group level. In 
addition, when compared to the other disease activity indices, had the strongest 
association with the mHAQ (r=0.58).  This would be expected given that the 
mHAQ is a component of the mDAS28.  Makinen et al (12) noted when 
developing the Mean Overall Index for Rheumatoid Arthritis (MOI-RA) that one of 
the limitations of the DAS28 was that it did not contain the Health Assessment 
Questionnaire (HAQ), (33) considered the best predictor of outcomes in RA (34-
36). In several studies comparing the HAQ with the mHAQ, both measures were 
strongly correlated (37) and sensitive to change of treatment (38-40). Since a 
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measure should have face validity, the addition of the mHAQ as part of the 
mDAS28 strengthens the overall credibility of the measure.  
 The mean baseline values of the mDAS28 were almost identical to the 
mean baseline values of the DAS28 in all 3 cohorts (cross-sectional 
development: 3.41 (1.38) vs. 3.42 (1.57); cross-sectional validation: 3.40(1.37) 
vs. 3.41(1.54); longitudinal validation: 4.21(1.41) vs. 4.19 (1.59). When 
classifying proportions of individual patients into the disease states of remission, 
low, moderate and high disease activity, the mDAS28 performed again almost 
identically to the DAS28. The DAS28 classified 16% and 35% of patients into 
remission and low disease activity, respectively while the mDAS28 classified 
16% and 34% into remission and low disease activity.   
Since measurement tools need to assess individual patients, we examined 
the agreement of the measures when classifying individual patients according to 
disease levels, the mDAS28 strongly agreed with the DAS28 (ĸ= 0.70), despite 
the absence of the ESR as a component. The mDAS28 was also compared to 
the DAS28 when classifying patients according to their level of response using 
the EULAR response criteria. Strong agreement was found between the 
mEULAR and the EULAR (ĸ= 0.74). However, only moderate agreement was 
found when the mEULAR was compared with the CDAI and SDAI response 
criteria. The EULAR was also moderately in agreement with the CDAI and SDAI 
response criteria.   
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 The mean change (SD) in scores of the mDAS28 and the DAS28 from 
baseline initiation to the follow-up visit were similar (∆=0.698 (1.20) vs. ∆=0.732 
(1.28)). In addition, the mDAS28 demonstrated similar sensitivity to detect 
disease activity changes after initiation of a DMARD when compared to the 
DAS28.  This finding has important clinical implications for consistent monitoring 
of treatment response in the clinical setting and for observational research.   
 A limitation of the study is the use of only one observational data set to 
develop and validate the measure. Additional validations of the mDAS28 should 
be performed in other populations such as a clinic trial dataset. Another potential 
criticism of the study could be that the patients used had low to moderate 
disease activity. Again additional investigations of the mDAS28 using populations 
with greater ranges of disease levels including high disease activity should be 
undertaken. The reproducibility and reliability of the mDAS28, although not 
examined in this study, have been satisfied, based on the proven reliability of its 
individual components.   
  Our intent at modifying the DAS28 by substituting other measures for the 
ESR was not to diminish the importance of the ESR as a measure of RA disease 
activity. In effect, we suggest physicians continue to order lab measures regularly 
in the clinic as the ESR is an important measure of disease activity and long term 
outcomes. Modification of the DAS28 was done in an effort to allow the 
computation of a comparable measure to the DAS28 to be computed in standard 
care and for research settings where laboratory values such as the ESR are 
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either not available, or the results are available after the clinical encounter and 
not incorporated into the decision making process by providers.  
 In this observational study, we have developed a modified version of the 
DAS28, calculated without the ESR value and then demonstrated that it is 
comparable to the DAS28 when measuring RA disease activity and response. 
The mDAS28 was also found to be a valid outcome measure as it fulfilled most of 
the criterion recommended by the OMERACT initiative.  The mDAS28 can be 
calculated when ESR values are unavailable, preventing patients from being 
omitted in epidemiological research using disease registries. Further testing of 
the mDAS28 in other patient populations is recommended.  
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Table 4.1 Demographic and clinical characteristics in cross-sectional and 
longitudinal cohorts* 
 Cross-sectional Longitudinal† 
 Development Validation  Validation 
 
Patients (n) 
 
5729 5578 
 
367 
 
      Age, years 60.1 (13.7) 60.3 (13.8) 
 
58.7 (12.5) 
 
      Gender, % female 75.8 75.3  
 
77.9 
       
      Race, % Caucasian 
 
82.7 
 
82.5 
 
85.3  
     
      Rheumatoid factor (% positive) 
 
67.8 
 
70 
 
82 
     
      Disease duration, years 
 
11.3 (10.1) 
 
11.1 (9.9) 
 
11.8 (10.0) 
 
Disease activity characteristics 
 
   
     
      Tender joints  0-28 
 
3.37 (5.54) 
 
3.38 (5.4) 
 
5.65 (6.10) 
     
      Swollen joints 0-28 
 
3.89 (5.54) 
 
3.86 (5.53) 
 
5.98 (5.50) 
     
      ESR (mm; normal <20) 
 
24.6 (22.3) 
 
24.6 (22.1) 
 
25.9 (22.6) 
     
      CRP (mg/dL; normal <1.0) 
 
2.96 (8.5) 
 
2.96 (8.7) 
 
2.8 (7.8) 
     
      Pain (VAS) assessment 0-100 
 
32.2 (26.6) 
 
31.6 (25.9) 
 
39.4 (26.7) 
     
      mHAQ, 0-3 
 
0.40 (0.49) 
 
0.39 (0.48) 
 
0.50 (0.52) 
      
      Patient global assessment, 0-  
      100 
 
29.9 (25.9) 
 
29.8 (25.9) 
 
37.9 (26.84) 
      
      Physician global assessment, 0- 
      100 
 
19.5 (19.0) 
 
19.4 (19.2) 
29.4 (20.3) 
       
      Duration of Stiffness (hours) 
 
1.03 (2.4) 
 
0.94 (2.11) 
 
1.34 (3.11) 
 
Disease activity composite measures 
 
  
      
      mDAS28  
 
3.41 (1.38) 
 
3.40 (1.37) 
 
4.21 (1.41) 
      
      DAS28  
 
3.42 (1.54) 
 
3.41 (1.54) 
 
4.19 (1.59) 
      
      SDAI 
 
15.0 (16.1) 
 
14.9 (16.0) 
 
20.5 (17.0) 
      
      CDAI 
 
12.2 (12.0) 
 
12.1( 12.0) 
 
18.4 (13.0)  
*Values are the mean (SD) unless otherwise indicated; † Initiators of disease-modifying anti-rheumatic 
drugs (DMARDs);  ESR= erythrocyte sedimentation rate; CRP=C-reactive protein; VAS= visual analogue 
scale; mHAQ= modified Health Assessment Questionnaire score; mDAS28= modified Disease Activity 
Score with 28 joint count; DAS28= Disease Activity Score with 28 joint count; SDAI=Simplified Disease 
Activity Index; CDAI= Clinical Disease Activity Index.  
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Table 4.2 Results of Forward and Backwards Stepwise Linear Regressions 
 
 
Predictors 
 
Coefficient 
(β)  
Standard 
Error 
P>|t| 
 
95% CI 
 
Disability Index (mHAQ) 
 
0.345 
 
0.033 
 
0.000 
 
(0.280 to 0.411) 
 
Physician Global 
Assessment 
 
0.077 
 
0.001 
 
0.000 
 
(0.006 to 0.009) 
 
Swollen Joint Score 
 
0.041 
 
0.011 
 
0.000 
 
(0.019 to 0.062) 
 
Patient VAS for pain 
 
0.001 
 
0.001 
 
0.033 
 
(0.000 to 0.003) 
 
Tender Joint Score 
 
-0.037 
 
0.013 
 
0.004 
 
(-0.064 to -
0.012) 
 
Constant   
 
2.423 
 
0.022 
 
0.000 
 
(2.378 to 2.467)  
mHAQ= modified Health Assessment Questionnaire; VAS= Visual analog scale  
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Table 4.3 Proportion of patients classified in disease levels using composite 
indices in the cross-sectional validation cohort (n=5578)*  
 
Measure 
 
Remission 
N (%) 
Low 
N (%) 
Moderate 
N (%) 
High 
N (%) 
 
mDAS28 
 
1939 (35) 
 
915 (17) 
 
1,936 (35) 
 
732 (13) 
 
DAS28 
 
1871 (34) 
 
894 (16) 
 
1,970 (35) 
 
843 (15) 
 
CDAI 
 
1309 (23) 
 
1874 (34) 
 
1,387 (25) 
 
1,008 (18) 
 
SDAI† 
 
618 (20) 
 
1050 (34) 
 
852 (28) 
 
537 (18)  
*Values are numbers (%); mDAS28= modified Disease Activity Score with 28 
joint count; DAS28=Disease Activity Score with 28 joint count; CDAI= Clinical 
Disease Activity Index; SDAI= Simplified Disease Activity Index;  
†For the SDAI, n=3057 had SDAI scores.  
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Table 4.4 Sensitivity to change assessed by effect size (ES) and standardized 
response mean (SRM)* 
 
 
Measure 
 
Baseline 
Mean (SD) 
 
Follow-up 
Mean (SD) 
 
Change 
Mean (SD) 
 
ES 
 
SRM 
 
mDAS28 
 
4.21 (1.41) 
 
3.50 (1.31) 
 
0.698 (1.20) 
 
0.50 
 
0.58 
 
DAS28 
 
4.22 (1.55) 
 
3.48 (1.48) 
 
0.732 (1.28) 
 
0.47 
 
0.57 
 
CDAI 
 
18.37 (13.05) 
 
12.49 (11.19) 
 
5.88 (11.28) 
 
0.45 
 
0.52 
 
SDAI 
 
20.54 (17.04) 
 
14.23 (11.75) 
 
6.33 (14.17) 
 
0.37 
 
0.45 
 
*Values are the mean (SD) unless otherwise indicated; mDAS28= modified 
Disease Activity Score with 28 joint count; DAS28=Disease Activity Score with 28 
joint count; CDAI= Clinical Disease Activity Index; SDAI= Simplified Disease 
Activity Index. 
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Value of composite 
measure at 
endpoint  
Improvement in composite measure from 
baseline  
     >1.2†         >0.6 and ≤1.2              ≤0.6 
  
  ≤3.2* 
   
Good 
 
     
Moderate       
 
 
   
None 
 
   >3.2 and ≤5.1 
 
 
 
   >5.1 
 
* DAS28 absolute cut points; †DAS28 change cut points; 
 
  
Figure 4.1 Algorithm to calculate the EULAR Response Criteria using published 
absolute and change cut points. 
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Figure 4.2 Distribution properties of composite disease activity indices in the 
cross-sectional validation cohort (n=5578).  
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CHAPTER V 
 
Final Conclusions and General Discussions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                            
134
 
The research presented in this dissertation is focused on improving clinical 
management of rheumatoid arthritis and epidemiological research efforts by 
evaluating and developing clinical measures of disease activity and treatment 
response to prevent further disease progression. Factors predictive of physician 
practice behaviors specifically in the measurement of acute phase reactants and 
prescription of disease-modifying antirheumatic drug (DMARD) therapy, were 
also elucidated in this work. The first study in this thesis showed that the two 
measures of disease activity, the Clinical Disease Activity Index (CDAI) (1) and 
the Disease Activity Score with 28 joint count (DAS28) (2, 3) are valid measures 
for use in clinical care to assess disease activity but not to guide DMARD 
treatment decisions. Further, several patient and clinic characteristics were found 
to be predictive of physician DMARD prescribing behavior and the variability in 
the prescription of DMARDs by rheumatologists was quantified.  The second 
study elucidated factors predictive of the measurement of erythrocyte 
sedimentation rate (ESR) and C-reactive protein (CRP). These factors included 
ordering of other laboratory tests, the number of previous DMARDs prescribed, 
patient age, no insurance, physician propensity to order ESR or CRP and private 
clinic. While a previous study (4) reported that physician practice style influenced 
ESR and CRP measurement, our results found that individual physician 
characteristics had little to do with their measurement but patient and clinic 
characteristics were very influential. In addition, disease activity was found not to 
be associated with a physician’s decision to measure ESR or CRP. In the third 
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study, a new measure of disease activity, the modified DAS28 was developed 
and validated. The results of the study showed that it was a comparable measure 
to the DAS28 and could be used in epidemiological research studies when the 
DAS28 was not calculable due to missing ESR values.  
 
Validation of CDAI and DAS28 as Measures to Guide Clinical Treatment  
 
Decisions  
 
Previous studies have examined the performance of the CDAI and the 
DAS28 for use in the clinical setting to consistently monitor disease activity and 
treatment response to ensure optimal treatment effectiveness (5-13). Yet, 
whether the CDAI and DAS28 can be used to guide treatment decisions in the 
clinic has not been illuminated, to the best of my knowledge in the literature. The 
association of CDAI and the rheumatologist’s decision to change DMARD 
therapy was examined using a multi-level mixed logistic regression modeling 
strategy to accommodate the hierarchical data structure of the data. The DAS28 
as a predictor of treatment decision was also examined in a second analysis. 
Correlates that might influence the rheumatologist to change DMARD therapy 
were identified and variability in the rheumatologists’ decisions to change 
DMARD therapy was quantified.  The study showed that the CDAI and DAS28 
were both significantly associated with the physicians’ decision to change 
DMARD therapy. Correlates that were significantly predictive of change in 
treatment included nonbiologic DMARD initiation at baseline, number of past 
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DMARDS prescribed, patient age, duration of disease, employment status, 
physician age and academic clinic. The effect of patient characteristics on the 
rheumatologists’ decision to change DMARD therapy was found to be substantial 
with little variation related to clinic or individual physicians. Based on these 
results, future interventions to improve DMARD prescription behavior should be 
targeted at the heterogeneity of patients and not physicians or clinics.  The 
abilities of the CDAI and DAS28 to discriminate a change in DMARD therapy 
were fair with an AUC of 0.69 and 0.72, respectively. Thus, the study could not 
validate the CDAI and DAS28 as measures to guide treatment in the clinic.  
 
ESR and CRP Measurement Not Associated with Disease Activity  
Acute phase reactants (APRs), ESR and CRP, long used in the clinic to 
measure disease activity in rheumatoid arthritis were recently investigated and 
concerns over their appropriateness as measures of disease activity were raised 
(14). In addition, variability in their measurement in the clinic has been reported, 
impeding the calculation of the DAS28 and SDAI. To examine why variability in 
the measurement of these APRs exists, correlates that may be influencing 
measurement of ESR and CRP in the clinic, were examined. Other laboratory 
tests ordered at the same clinical encounter, number of past DMARDs 
prescribed, type of clinic and insurance status were the strongest predictors of 
the measurement of ESR and CRP. Remarkably, since ESR and CRP testing 
has been long utilized to monitor patient’s disease activity, no quantitative 
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measures of disease activity were significantly predictive of the measurement of 
ESR or CRP.  This finding supports the results of the recent study noted above 
and warrants the further investigation of the ESR and CRP as measures of 
disease activity. Variability in the measurement of ESR and CRP was found to be 
due to unmeasured clinic and patient characteristics and not the individual 
physician, in contrast to the results from a prior study (4) that found 
measurement variation was due to the individual physician. In addition, large 
variation in the measurement of ESR and CRP was found in our study again in 
contrast with another prior study that found little variation (15).    
 
A New Simplified Measure of Disease Activity and Treatment Response   
Since the variability in the measurement of ESR and CRP may impede the 
calculation of the DAS28 and the SDAI and limit their use in the clinic, we 
developed and validated a new simplified composite measure. The measure was 
developed by identifying calculable disease activity measures that might 
significantly predict the value of ESR. These predictive factors were then imputed 
into the DAS28 formula in place of the ESR value. The new measure, named the 
modified DAS28 (mDAS28), was then validated as a measure of disease activity 
and treatment response. Our findings demonstrated that the performance of this 
new measure, mDAS28, was comparable with the DAS28 and we concluded that 
the mDAS28 could be used in the clinical setting to consistently monitor disease 
activity and response to treatment when the DAS28 could not be calculated.     
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Summary   
In summary, the three studies detailed in this dissertation have focused on 
improving the clinical management of patients with rheumatoid arthritis and 
epidemiological research efforts in RA. The findings that two composite 
measures, CDAI and DAS28, cannot guide treatment decisions in the clinic, that 
two established disease activity measures, ESR and CRP are not associated 
with disease activity and that the DAS28 can be modified by replacing the ESR 
with calculable clinical variables and its modified version validated, have 
significantly advanced our knowledge of disease activity and treatment response 
measurement in the clinic. Elucidation of these aspects of disease activity 
measurement may enable the improvement in the management of rheumatoid 
arthritis in the clinic setting, facilitate the inclusion of more patients in 
epidemiological research studies and ultimately improve the disease outcomes 
for patients.       
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